

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT


(10) International Publication Number
WO 01/36422 A1

- (51) International Patent Classification⁷: C07D 487/04, 495/14, 491/14, A61K 31/505, A61P 9/12 // (C07D 487/04, 239:00, 231:00) (C07D 495/14, 335:00, 239:00, 231:00) (C07D 491/14, 307:00, 239:00, 231:00)
- (72) Inventors: HOLLADAY, Mark, W.; 6480 East Placita Acambay, Tucson, AZ 85750 (US). CARROLL, William, A.; 2514 Prairie, Apt. 3B, Evanston, IL 60201 (US). DRIZIN, Irene; 16764 West Cherrywood Lane, Wadsworth, IL 60083 (US). YI, Lin; 1738 Hillside Court, Gurnee, IL 60031 (US). ZHANG, Henry, Q.; 107 Suffolk Lane, Grayslake, IL 60030 (US).
- (21) International Application Number: PCT/US00/32333
- (22) International Filing Date:
17 November 2000 (17.11.2000)
- (74) Agents: WARD, Michael, J. et al.; Dept. 377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).
- (25) Filing Language: English (81) Designated States (national): CA, JP, MX.
- (26) Publication Language: English (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (30) Priority Data:
09/443,212 19 November 1999 (19.11.1999) US
09/709,923 10 November 2000 (10.11.2000) US
- Published:
— With international search report.
- (71) Applicant: ABBOTT LABORATORIES [US/US]; Dept. 377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/36422 A1

(54) Title: TRICYCLIC DIHYDROPYRIMIDINE POTASSIUM CHANNEL OPENERS



(57) Abstract: Compounds of formula (I), are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

TRICYCLIC DIHYDORPYRIMIDINE POTASSIUM CHANNEL OPENERS

TECHNICAL FIELD

5 Novel tricyclic dihydropyrimidine compounds and their derivatives can open potassium channels and are useful for treating a variety of medical conditions.

BACKGROUND OF INVENTION

Potassium channels play an important role in regulating cell membrane excitability.

10 When the potassium channels open, changes in the electrical potential across the cell membrane occur and result in a more polarized state. A number of diseases or conditions may be treated with therapeutic agents that open potassium channels; for example, see K. Lawson, *Pharmacol. Ther.*, v. 70, pp. 39-63 (1996); D.R. Gehlert et al., *Prog. Neuro-Psychopharmacol & Biol. Psychiat.*, v. 18, pp. 1093-1102 (1994); M. Gopalakrishnan et al., *Drug Development*

15 *Research*, v. 28, pp. 95-127 (1993); J.E. Freedman et al., *The Neuroscientist*, v. 2, pp. 145-152 (1996); D. E. Nurse et al., *Br. J. Urol.*, v. 68 pp. 27-31 (1991); B. B. Howe et al., *J. Pharmacol. Exp. Ther.*, v. 274 pp. 884-890 (1995); D. Spanswick et al., *Nature*, v. 390 pp. 521-25 (December 4, 1997); Dompeling Vasa. *Supplementum* (1992) 3434; WO9932495; Grover, *J Mol Cell Cardiol.* (2000) 32, 677; and Buchheit, *Pulmonary Pharmacology &*

20 *Therapeutics* (1999) 12, 103. Such diseases or conditions include asthma, hypertension, epilepsy, male sexual dysfunction, female sexual dysfunction, pain, bladder overactivity, stroke, diseases associated with decreased skeletal blood flow such as Raynaud's phenomenon and intermittent claudication, eating disorders, functional bowel disorders, neurodegeneration, benign prostatic hyperplasia (BPH), dysmenorrhea, premature labor, alopecia,

25 cardioprotection, coronary artery disease, angina and ischemia.

Bladder overactivity is a condition associated with the spontaneous, uncontrolled contractions of the bladder smooth muscle. Bladder overactivity thus is associated with or

can cause diseases and/or conditions such as sensations of urgency, urinary incontinence, pollakiuria, bladder instability, nocturia, bladder hyperreflexia, and enuresis (Resnick, *The Lancet* (1995) 346, 94-99; Hampel, *Urology* (1997) 50 (Suppl 6A), 4-14; Bosch, *BJU International* (1999) 83 (Suppl 2), 7-9). Potassium channel openers (KCOs) act as smooth muscle relaxants. Because bladder overactivity and urinary incontinence can result from the spontaneous, uncontrolled contractions of the smooth muscle of the bladder, the ability of potassium channel openers to hyperpolarize bladder cells and relax bladder smooth muscle may provide a method to ameliorate or prevent bladder overactivity, pollakiuria, bladder instability, nocturia, bladder hyperreflexia, urinary incontinence, and enuresis (Andersson, *Urology* (1997) 50 (Suppl 6A), 74-84; Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63; Nurse, *Br. J. Urol.*, (1991) 68, 27-31; Howe, *J. Pharmacol. Exp. Ther.*, (1995) 274, 884-890; Gopalakrishnan, *Drug Development Research*, (1993) 28, 95-127).

The irritative symptoms of BPH (urgency, frequency, nocturia and urge incontinence) have been shown to be correlated to bladder instability (Pandita, *The J. of Urology* (1999) 162, 943). Therefore the ability of potassium channel openers to hyperpolarize bladder cells and relax bladder smooth muscle may provide a method to ameliorate or prevent the symptoms of BPH. (Andersson; *Prostate* (1997) 30: 202-215).

The excitability of corpus cavernosum smooth muscle cells is important in the male erectile process. The relaxation of corporal smooth muscle cells allows arterial blood to build up under pressure in the erectile tissue of the penis leading to erection (Andersson, *Pharmacological Reviews* (1993) 45, 253). Potassium channels play a significant role in modulating human corporal smooth muscle tone, and thus, erectile capacity. By patch clamp technique, potassium channels have been characterized in human corporal smooth muscle cells (Lee, *Int. J. Impot. Res.* (1999) 11(4),179-188). Potassium channel openers are smooth muscle relaxants and have been shown to relax corpus cavernosal smooth muscle and induce erections (Andersson, *Pharmacological Reviews* (1993) 45, 253; Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63, Vick, *J. Urol.* (2000) 163: 202). Potassium channel openers therefore may have utility in the treatment of male sexual dysfunctions such as male erectile dysfunction, impotence and premature ejaculation.

The sexual response in women is classified into four stages: excitement, plateau, orgasm and resolution. Sexual arousal and excitement increase blood flow to the genital area, and lubrication of the vagina as a result of plasma transudation. Topical application of KCOs like minoxidil and nicorandil have been shown to increase clitoral blood flow (J.J. Kim, J.W. Yu, J.G. Lee, D.G. Moon, "Effects of topical K-ATP channel opener solution on clitoral blood flow", J. Urol. (2000) 163 (4): 240). KCOs may be effective for the treatment of female sexual dysfunction including clitoral erectile insufficiency, vaginismus and vaginal engorgement (I. Goldstein and J.R. Berman., "Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes"., Int. J. Impotence Res. (1998) 10:S84-S90), as KCOs can increase blood flow to female sexual organs.

Potassium channel openers may have utility as tocolytic agents to inhibit uterine contractions to delay or prevent premature parturition in individuals or to slow or arrest delivery for brief periods to undertake other therapeutic measures (Sanborn, Semin. Perinatol. (1995) 19, 31-40; Morrison, Am. J. Obstet. Gynecol. (1993) 169(5), 1277-85). Potassium channel openers also inhibit contractile responses of human uterus and intrauterine vasculature. This combined effect would suggest the potential use of KCOs for dysmenhorrea (Kostrzewska, Acta Obstet. Gynecol. Scand. (1996) 75(10), 886-91). Potassium channel openers relax uterine smooth muscle and intrauterine vasculature and therefore may have utility in the treatment of premature labor and dysmenorrhoea (Lawson, Pharmacol. Ther., (1996) 70, 39-63).

Potassium channel openers relax gastrointestinal smooth tissues and therefore may be useful in the treatment of functional bowel disorders such as irritable bowel syndrome (Lawson, Pharmacol. Ther., (1996) 70, 39-63).

Potassium channel openers relax airways smooth muscle and induce bronchodilation. Therefore potassium channel openers may be useful in the treatment of asthma and airways hyperreactivity (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Buchheit, Pulmonary Pharmacology & Therapeutics (1999) 12, 103; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).

Neuronal hyperpolarization can produce analgesic effects. The opening of potassium channels by potassium channel openers and resultant hyperpolarization in the membrane of target neurons is a key mechanism in the effect of opioids. The peripheral antinociceptive effect of morphine results from activation of ATP-sensitive potassium channels, which causes hyperpolarization of peripheral terminals of primary afferents, leading to a decrease in action potential generation (Rodrigues, Br J Pharmacol (2000) 129(1), 110-4). Opening of K_{ATP} channels by potassium channel openers plays an important role in the antinociception mediated by alpha-2 adrenoceptors and mu opioid receptors. KCOs can potentiate the analgesic action of both morphine and dexmedetomidine via an activation of K_{ATP} channels at the spinal cord level (Vergoni, Life Sci. (1992) 50(16), PL135-8; Asano, Anesth. Analg. (2000) 90(5), 1146-51).. Thus, potassium channel openers can hyperpolarize neuronal cells and have shown analgesic effects. Potassium channel openers therefore may be useful as analgesics in the treatment of various pain states including but not limited to migraine and dyspareunia (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Gehlert, Prog. Neuro-Psychopharmacol. & Biol. Psychiat., (1994) 18, 1093-1102).

Epilepsy results from the propagation of nonphysiologic electrical impulses. Potassium channel openers hyperpolarize neuronal cells and lead to a decrease in cellular excitability and have demonstrated antiepileptic effects. Therefore potassium channel openers may be useful in the treatment of epilepsy (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Gehlert, Prog. Neuro-Psychopharmacol. & Biol. Psychiat., (1994) 18, 1093-1102).

Neuronal cell depolarization can lead to excitotoxicity and neuronal cell death. When this occurs as a result of acute ischemic conditions, it can lead to stroke. Long-term neurodegeneration can bring about conditions such as Alzheimer's and Parkinson's diseases. Potassium channel openers can hyperpolarize neuronal cells and lead to a decrease in cellular excitability. Activation of potassium channels has been shown to enhance neuronal survival. Therefore potassium channel openers may have utility as neuroprotectants in the treatment of neurodegenerative conditions and diseases such as cerebral ischemia, stroke, Alzheimer's

disease and Parkinson's disease (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Gehlert, Prog. Neuro-Psychopharmacol & Biol. Psychiat., (1994) 18, 1093-1102; Freedman, The Neuroscientist (1996) 2, 145).

5 Potassium channel openers may have utility in the treatment of diseases or conditions associated with decreased skeletal muscle blood flow such as Raynaud's syndrome and intermittent claudication (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Dompeling Vasa. Supplementum (1992) 3434; and WO9932495).

10 Potassium channel openers may be useful in the treatment of eating disorders such as obesity (Spanswick, Nature, (1997) 390, 521-25; Freedman, The Neuroscientist (1996) 2, 145).

Potassium channel openers have been shown to promote hair growth therefore potassium channel openers have utility in the treatment of hair loss and baldness also known as alopecia (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).

15 Potassium channel openers possess cardioprotective effects against myocardial injury during ischemia and reperfusion. (Garlid, Circ. Res. (1997) 81(6), 1072-82). Therefore, potassium channel openers may be useful in the treatment of heart diseases (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Grover, J. Mol. Cell Cardiol. (2000) 32, 677).

20 Potassium channel openers, by hyperpolarization of smooth muscle membranes, can exert vasodilation of the collateral circulation of the coronary vasculature leading to increase blood flow to ischemic areas and could be useful for the coronary artery disease (Lawson, Pharmacol. Ther., (1996) 70, 39-63, Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).


25 US 4918074, EP 183848 B1, EP 217142, EP 328700, JP 63060985, JP 63243029, JP 61227584, and Atwal, K.S., Bioorg. Med. Chem. Lett (1991) 1, 291-294 disclose bicyclic 4,7-dihydropyrazolo[1,5-a]pyrimidines.

The compounds of the present invention are novel and hyperpolarize cell membranes, open potassium channels and relax smooth muscle cells.

5

SUMMARY OF THE INVENTION

In its principle embodiment, the present invention discloses compounds of formula (I):



or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof wherein,

10

n is an integer of 0-1;

m is an integer of 1-2;

provided that when m is 2, n is 0;

R^1 is selected from aryl and heterocycle;

Q is selected from C(O), S(O), and S(O)₂;

15

V is selected from C(R⁶)(R⁷), O, S, and NR², wherein R² is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are independently selected from hydrogen and lower alkyl;

20

R⁶ and R⁷ are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are as defined above;

25

R⁸ and R⁹ are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano,

cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above;

X is selected from N and CR^3 wherein R^3 is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above; and

D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above.


DETAILED DESCRIPTION OF THE INVENTION

All patents, patent applications, and literature references cited in the specification are herein incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure, including definitions, will prevail.

It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention.

Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, formulations and/or methods of use of the invention, may be made without departing from the spirit and scope thereof.

In its principle embodiment, the present invention discloses compounds of formula (I):



(I),

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof wherein,

n is an integer of 0-1;

m is an integer of 1-2;

5 provided that when m is 2, n is 0;

R¹ is selected from aryl and heterocycle;

Q is selected from C(O), S(O), and S(O)₂;

V is selected from C(R⁶)(R⁷), O, S, and NR², wherein R² is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are independently selected from hydrogen and lower alkyl;

R⁶ and R⁷ are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are as defined above;

R⁸ and R⁹ are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are as defined above;

X is selected from N and CR³ wherein R³ is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are as defined above; and


D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl,

hydroxy, hydroxyalkyl, oxo, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above.

In another embodiment of the present invention, compounds have formula (I) wherein, R^1 is aryl; X is CR^3 ; R^3 is hydrogen; and R^8 , R^9 , D, E, Q, V, m, and n are as defined in
5 formula (I).

In another embodiment of the present invention, compounds have formula (I) wherein, R^1 is heterocycle; X is CR^3 ; R^3 is hydrogen; and R^8 , R^9 , D, E, Q, V, m, and n are as defined in formula (I).

10 In a preferred embodiment, compounds of the present invention have formula (II):



(II),

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof wherein,

R^1 is selected from aryl and heterocycle;

15 Q is selected from C(O), S(O), and S(O)₂;

V is selected from C(R^6)(R^7), O, S, and NR², wherein R^2 is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are
20 independently selected from hydrogen and lower alkyl;

R^6 and R^7 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined
25 above;

R^8 and R^9 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano,

cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above; and

5 D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above.

10 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R^1 is heterocycle; Q is C(O); and R^8 , R^9 , D, E, and V are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R^1 is heterocycle; Q is S(O); and R^8 , R^9 , D, E, and V are as defined in formula (I).

15 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R^1 is heterocycle; Q is S(O)₂; and R^8 , R^9 , D, E, and V are as defined in formula (I).

20 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R^1 is heterocycle; Q is C(O); V is S; and R^8 , R^9 , D, and E are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R^1 is heterocycle; Q is C(O); V is S; and R^8 , R^9 , D, and E are hydrogen.

25 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R^1 is heterocycle; Q is C(O); V is CH₂; and R^8 , R^9 , D, and E are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R^1 is heterocycle; Q is C(O); V is CH₂; E is alkyl; D is alkyl; and R^8 and R^9 are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is heterocycle; Q is C(O); V is CH₂; E is alkyl; D is alkyl; and R⁸ and R⁹ are hydrogen.

5 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is heterocycle; Q is C(O); V is CH₂; and R⁸, R⁹, D, and E are hydrogen.

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is heterocycle; Q is S(O)₂; V is CH₂; and R⁸, R⁹, D, and E are as defined in formula (I).

10 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is heterocycle; Q is S(O)₂; V is CH₂; and R⁸, R⁹, D, and E are hydrogen.

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); and R⁸, R⁹, D, E, and V are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is S; and R⁸, R⁹, D, and E are as defined in formula (I).

15 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is S; and R⁸, R⁹, D, and E are hydrogen.

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; and R⁸, R⁹, D, and E are as defined in formula (I).

20 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; D is alkyl; E is alkyl; and R⁸ and R⁹ are as defined in formula (I).

25 In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; D is alkyl; E is alkyl; and R⁸ and R⁹ are hydrogen.

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; R⁹ is aryl; and R⁸, D, and E are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; R⁹ is aryl; and R⁸, D, and E are hydrogen.

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; R⁹ is heterocycle; and R⁸, D, and E are as
5 defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; R⁹ is heterocycle; and R⁸, D, and E are hydrogen.

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; R⁹ is halogen; and R⁸, D, and E are as defined in
10 formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; R⁹ is halogen; and R⁸, D, and E are hydrogen.

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is C(O); V is CH₂; and R⁸, R⁹, D, and E are hydrogen.


In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is S(O); and R⁸, R⁹, D, E, and V are as defined in formula (I).
15

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is S(O)₂; and R⁸, R⁹, D, E, and V are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is S(O)₂; V is CH₂; and R⁸, R⁹, D, and E are as defined in formula
20 (I).

In another preferred embodiment of the present invention, compounds have formula (II) wherein, R¹ is aryl; Q is S(O)₂; V is CH₂; and R⁸, R⁹, D, and E are hydrogen.

In another preferred embodiment, compounds of the present invention have
25 formula (III):



(III),

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof wherein,

R¹ is selected from aryl and heterocycle;

Q is selected from C(O), S(O), and S(O)₂;

5 V is selected from C(R⁶)(R⁷), O, S, and NR², wherein R² is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are independently selected from hydrogen and lower alkyl;

10 R⁶ and R⁷ are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are as defined above;

15 R⁸ and R⁹ are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are as defined above;
and

20 D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR⁴R⁵, and (NR⁴R⁵)alkyl wherein R⁴ and R⁵ are as defined above.

25 In another preferred embodiment of the present invention, compounds have formula (III) wherein, R¹ is heterocycle; Q is C(O); and R⁸, R⁹, D, E, and V are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (III) wherein, R^1 is heterocycle; Q is S(O); and R^8 , R^9 , D, E, and V are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (III) wherein, R^1 is heterocycle; Q is S(O)₂; and R^8 , R^9 , D, E, and V are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (III) wherein, R^1 is aryl; Q is C(O); and R^8 , R^9 , D, E, and V are as defined in formula (I).


In another preferred embodiment of the present invention, compounds have formula (III) wherein, R^1 is aryl; Q is C(O); V is O; and R^8 , R^9 , D, and E are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (III) wherein, R^1 is aryl; Q is C(O); V is O; and R^8 , R^9 , D, and E are hydrogen.

In another preferred embodiment of the present invention, compounds have formula (III) wherein, R^1 is aryl; Q is S(O); and R^8 , R^9 , D, E, and V are as defined in formula (I).

In another preferred embodiment of the present invention, compounds have formula (III) wherein, R^1 is aryl; Q is S(O)₂; and R^8 , R^9 , D, E, and V are as defined in formula (I).

In another preferred embodiment, compounds of the present invention have formula (IV):



(IV),

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof wherein,

R^1 is selected from aryl and heterocycle;

Q is selected from C(O), S(O), and S(O)₂;

V is selected from C(R⁶)(R⁷), O, S, and NR², wherein R² is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle,

heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are independently selected from hydrogen and lower alkyl;

R^6 and R^7 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, 5 cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above;

R^8 and R^9 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, 10 cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above; and

D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, 15 cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are as defined above.

In another preferred embodiment of the present invention, compounds have formula (IV) wherein, R^1 is heterocycle; Q is C(O); R^8 , R^9 , D, and E are as defined in formula (I); and 20 V is as defined in formula (IV).

In another preferred embodiment of the present invention, compounds have formula (IV) wherein, R^1 is heterocycle; Q is S(O); R^8 , R^9 , D, and E are as defined in formula (I); and V is as defined in formula (IV).

In another preferred embodiment of the present invention, compounds have formula 25 (IV) wherein, R^1 is heterocycle; Q is S(O)₂; R^8 , R^9 , D, and E are as defined in formula (I); and V is as defined in formula (IV).

In another preferred embodiment of the present invention, compounds have formula (IV) wherein, R^1 is aryl; Q is C(O); R^8 , R^9 , D, and E are as defined in formula (I); and V is as defined in formula (IV).

In another preferred embodiment of the present invention, compounds have formula (IV) wherein, R¹ is aryl; Q is S(O); R⁸, R⁹, D, and E are as defined in formula (I); and V is as defined in formula (IV).

5 In another preferred embodiment of the present invention, compounds have formula (IV) wherein, R¹ is aryl; Q is S(O)₂; R⁸, R⁹, D, and E are as defined in formula (I); and V is as defined in formula (IV).

10 Another embodiment of the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.

15 Another embodiment of the invention relates to a method of treating male sexual dysfunction including, but not limited to, male erectile dysfunction and premature ejaculation, comprising administering a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

20 Another embodiment of the invention relates to a method of treating female sexual dysfunction including, but not limited to, female anorgasmia, clitoral erectile insufficiency, vaginal engorgement, dyspareunia, and vaginismus comprising administering a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

25 Yet another embodiment of the invention relates to a method of treating asthma, epilepsy, Raynaud's syndrome, intermittent claudication, migraine, pain, bladder overactivity, pollakiuria, bladder instability, nocturia, bladder hyperreflexia, eating disorders, urinary incontinence, enuresis, functional bowel disorders, neurodegeneration, benign prostatic hyperplasia (BPH), dysmenorrhea, premature labor, alopecia, cardioprotection, and ischemia comprising administering a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Definition of Terms

As used throughout this specification and the appended claims, the following terms have the following meanings.

5 The term "alkenyl," as used herein, refers to a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of "alkenyl" include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl and the like.

10 The term "alkenyloxy," as used herein, refers to an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein. Representative examples of alkenyloxy include, but are not limited to, propen-3-yloxy (allyloxy), buten-4-yloxy, and the like.

15 The term "alkoxy," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy and the like.

20 The term "alkoxyalkoxy," as used herein, refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through another alkoxy group, as defined herein. Representative examples of alkoxyalkoxy include, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy, 2-methoxyethoxy, methoxymethoxy, and the like.

The term "alkoxyalkyl," as used herein, refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, methoxymethyl, and the like.

25 The term "alkoxycarbonyl," as used herein, refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, and the like.

The term "alkyl," as used herein, refers to a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.

The term "alkylcarbonyl," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, 1-oxopentyl, and the like.

The term "alkylcarbonyloxy," as used herein, refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, tert-butylcarbonyloxy, and the like.

The term "alkylsulfinyl," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfinyl group, as defined herein. Representative examples of alkylsulfinyl include, but are not limited, methylsulfinyl, ethylsulfinyl, and the like.

The term "alkylsulfonyl," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkylsulfonyl include, but are not limited, methylsulfonyl, ethylsulfonyl, and the like.

The term "alkylthio," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a thio moiety, as defined herein. Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, hexylthio, and the like.

The term "alkynyl," as used herein, refers to a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, 1-butynyl and the like.

The term "aryl," as used herein, refers to a monocyclic carbocyclic ring system or a bicyclic carbocyclic fused ring system having one or more aromatic rings. Representative examples of aryl include, azulenyl, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like.

5 The aryl groups of this invention can be substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, aryl, aryloxy, azido, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, formyl, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, mercapto, nitro, sulfamyl, sulfo, sulfonate, $-NR^{80}R^{81}$
10 (wherein, R^{80} and R^{81} are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl and formyl), and $-C(O)NR^{82}R^{83}$ (wherein, R^{82} and R^{83} are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl).

The term "arylalkenyl," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkenyl group, as defined herein.
15 Representative examples of arylalkenyl include, but are not limited to, 2-phenylethenyl, 3-phenylpropen-2-yl, 2-naphth-2-ylethenyl, and the like.

The term "arylalkoxy," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
20 Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3-naphth-2-ylpropoxy, 5-phenylpentyloxy, and the like.

The term "arylalkoxycarbonyl," as used herein, refers to an arylalkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of arylalkoxy include, but are not limited to, benzyloxycarbonyl, naphth-2-ylmethoxycarbonyl, and the like.

25 The term "arylalkyl," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-naphth-2-ylethyl, and the like.

The term "aryloxy," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein. Representative examples of aryloxy include, but are not limited to, phenoxy, naphthyloxy, and the like.

5 The term "azido," as used herein, refers to an $-N_3$ group.

The term "carbonyl," as used herein, refers to a $-C(O)-$ group.

The term "carboxy," as used herein, refers to a $-CO_2H$ group.

The term "carboxy protecting group," as used herein, refers to a carboxylic acid protecting ester group employed to block or protect the carboxylic acid functionality while the reactions involving other functional sites of the compound are carried out. Carboxy-protecting groups are disclosed in T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991), which is hereby incorporated herein by reference. In addition, a carboxy-protecting group can be used as a prodrug whereby the carboxy-protecting group can be readily cleaved in vivo, for example by enzymatic hydrolysis, to release the biologically active parent. T. Higuchi and V. Stella provide a thorough discussion of the prodrug concept in "Pro-drugs as Novel Delivery Systems", Vol 14 of the A.C.S. Symposium Series, American Chemical Society (1975), which is hereby incorporated herein by reference. Such carboxy-protecting groups are well known to those skilled in the art, having been extensively used in the protection of carboxyl groups in the penicillin and cephalosporin fields, as described in U.S. Pat. No. 3,840,556 and 3,719,667, the disclosures of which are hereby incorporated herein by reference. Examples of esters useful as prodrugs for compounds containing carboxyl groups can be found on pages 14-21 of "Bioreversible Carriers in Drug Design: Theory and Application", edited by E.B. Roche, Pergamon Press, New York (1987), which is hereby incorporated herein by reference. Representative carboxy-protecting groups are loweralkyl (e.g., methyl, ethyl or tertiary butyl and the like); benzyl (phenylmethyl) and substituted benzyl derivatives thereof such substituents are selected from alkoxy, alkyl, halogen, and nitro groups and the like.

25 The term "cyano," as used herein, refers to a $-CN$ group.

The term "cycloalkyl," as used herein, refers to a saturated cyclic hydrocarbon group containing from 3 to 8 carbons. Representative examples of cycloalkyl include, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

5 The term "cycloalkylalkyl," as used herein, refers to cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl and 4-cycloheptylbutyl, and the like.

The term "formyl," as used herein, refers to a -C(O)H group.

10 The term "halo" or "halogen," as used herein, refers to -Cl, -Br, -I or -F.

The term "haloalkyl," as used herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, and the like.

15 The term "haloalkoxy," as used herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of haloalkoxy include, but are not limited to, 2-chloroethoxy, difluoromethoxy, 1,2-difluoroethoxy, 2,2,2-trifluoroethoxy, trifluoromethoxy, and the like.

20 The term "heterocycle," as used herein, refers to a monocyclic- or a bicyclic-ring system. Monocyclic ring systems are exemplified by any 5 or 6 membered ring containing 1, 2, 3, or 4 heteroatoms independently selected from oxygen, nitrogen and sulfur. The 5 membered ring has from 0-2 double bonds and the 6 membered ring has from 0-3 double bonds. Representative examples of monocyclic ring systems include, but are not limited to, azetidine, azepine, aziridine, diazepine, 1,3-dioxolane, dioxane, dithiane, furan, imidazole, 25 imidazoline, imidazolidine, isothiazole, isothiazoline, isothiazolidine, isoxazole, isoxazoline, isoxazolidine, morpholine, oxadiazole, oxadiazoline, oxadiazolidine, oxazole, oxazoline, oxazolidine, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridine, pyrimidine, pyridazine, pyrrole, pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, tetrazine, tetrazole, thiadiazole, thiadiazoline, thiadiazolidine, thiazole,

thiazoline, thiazolidine, thiophene, thiomorpholine, thiomorpholine sulfone, thiopyran, triazine, triazole, trithiane, and the like. Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or another monocyclic ring system as defined herein. Representative
5 examples of bicyclic ring systems include but are not limited to, for example, benzimidazole, benzothiazole, benzothiadiazole, benzothiophene, benzoxadiazole, benzoxazole, benzofuran, benzopyran, benzothiopyran, benzodioxine, 1,3-benzodioxole, cinnoline, indazole, indole, indoline, indolizine, naphthyridine, isobenzofuran, isobenzothiophene, isoindole, isoindoline, isoquinoline, phthalazine, pyranopyridine, quinoline, quinolizine, quinoxaline, quinazoline,
10 tetrahydroisoquinoline, tetrahydroquinoline, thiopyranopyridine, and the like.

The heterocycle groups of this invention can be substituted with 1, 2, or 3 substituents independently selected from alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyacetyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, aryl, azido, arylalkoxy, arylalkoxyacetyl, arylalkyl, aryloxy, carboxy, cyano, formyl, halogen,
15 haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, mercapto, nitro, sulfamyl, sulfo, sulfonate, -NR⁸⁰R⁸¹ (wherein, R⁸⁰ and R⁸¹ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl and formyl), and -C(O)NR⁸²R⁸³ (wherein, R⁸² and R⁸³ are independently selected from hydrogen, alkyl, aryl, and arylalkyl).

The term "heterocyclealkyl," as used herein, refers to a heterocycle, as defined herein,
20 appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heterocyclealkyl include, but are not limited to, pyrid-3-ylmethyl, 2-pyrimidin-2-ylpropyl, and the like.

The term "hydroxy," as used herein, refers to an -OH group.

The term "hydroxyalkyl," as used herein, refers to a hydroxy group, as defined herein,
25 appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, and the like.

The term "lower alkyl," as used herein, is a subset of alkyl as defined herein and refers to a straight or branched chain hydrocarbon group containing from 1 to 4 carbon atoms.

Representative examples of lower alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, and the like.

The term "mercapto," as used herein, refers to a -SH group.

The term "(NR⁴R⁵)alkyl," as used herein, refers to a -NR⁴R⁵ group, as defined herein,
5 appended to the parent molecular moiety through an alkyl group, as defined herein.

Representative examples of (NR⁴R⁵)alkyl include, but are not limited to, aminomethyl, dimethylaminomethyl, 2-(amino)ethyl, 2-(dimethylamino)ethyl, and the like.

The term "nitro," as used herein, refers to a -NO₂ group.

The term "oxo," as used herein, refers to a =O moiety.

10 The term "oxy," as used herein, refers to a -O- moiety.

The term "sulfamyl," as used herein, refers to a -SO₂NR⁹⁴R⁹⁵ group, wherein, R⁹⁴ and R⁹⁵ are independently selected from hydrogen, alkyl, aryl, and arylalkyl, as defined herein.

The term "sulfinyl," as used herein, refers to a -S(O)- group.

The term "sulfo," as used herein, refers to a -SO₃H group.

15 The term "sulfonate," as used herein, refers to a -S(O)₂OR⁹⁶ group, wherein, R⁹⁶ is selected from alkyl, aryl, and arylalkyl, as defined herein.

The term "sulfonyl," as used herein, refers to a -SO₂- group.

The term "thio," as used herein, refers to a -S- moiety.

Preferred compounds of formula (I) include, but are not limited to:

20 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-bromo-4-fluorophenyl)-5,9-dihydro-4H-pyrazolo[1,5-a]thiopyrano[3,4-d]pyrimidin-8(7H)-one;

9-(1-naphthyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(2-naphthyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

25 9-(3,4-dibromophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-bromophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-chlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

- 9-[4-chloro-3-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 9-[4-fluoro-3-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 5 9-[3-(trifluoromethoxy)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 9-(3-cyanophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 9-(3-methylphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 8-(3-bromo-4-fluorophenyl)-5,8-dihydro-4H,7H-furo[3,4-d]pyrazolo[1,5-a]pyrimidin-
- 10 7-one;
- (-) 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- (+) 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 15 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydro-4H-pyrazolo[1,5-a]thiopyrano[3,2-d]pyrimidine 8,8-dioxide,
- 9-(3-chloro-4-hydroxyphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 3-bromo-9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-
- 20 8(4H)-one;
- 9-(3-chloro-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 9-(3,4-difluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 9-(4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 9-[4-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 25 9-(4-cyanophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 9-(4-chloro-3-nitrophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
- 9-(4-chloro-3-fluorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-bromo-4-fluorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-[4-fluoro-3-(trifluoromethyl)phenyl]-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

5 9-(3,4-dichlorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(4-chloro-3-nitrophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

10 9-(3,4-dibromophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-[3-fluoro-4-(trifluoromethyl)phenyl]-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-nitrophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

15 9-(3-cyanophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

7,7-dimethyl-9-(5-nitro-3-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

20 9-(5-bromo-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(5-chloro-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(2-hydroxy-5-nitrophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

25 9-(3,5-dibromo-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-bromo-5-chloro-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3,5-dichloro-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3,4,5-trifluorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

5 9-(3,4-dichlorophenyl)-3-(3-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3,4-dichlorophenyl)-3-(3-chlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

10 9-(3,4-dichlorophenyl)-3-(4-carboxyphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3,4-dichlorophenyl)-3-[2-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

15 3-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

(+) 3-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

20 (-) 3-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

(+) 9-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;


(-) 9-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

25 9-(3,4-dichlorophenyl)-3-(2-furyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof.

Preparation of Compounds of The Invention

in (Dodd, J.H., *Journal of Heterocyclic Chemistry* 27 (1990) 1453; Terasawa, T., *Journal of Organic Chemistry* 42 (1977) 1163).


Scheme 3



Fused pyrimidines of general formula (8), wherein R^1 , X, Q, V, R^8 , R^9 , D, and E are as defined in formula (I), can be prepared according to the method of Scheme 3. A carbonyl component of general formula (7) can be treated with an aldehyde of general formula (2) and an amino heterocycle of general formula (3) in a solvent such as ethanol, acetonitrile or dimethylformamide with heating to provide fused pyrimidines of general formula (8). Carbonyl components of general formula (7) may be prepared as described in (Nakagawa, S., *Heterocycles* 13 (1979) 477; D'Angelo, J., *Tetrahedron Letters* 32 (1991) 3063).

10


Scheme 4



Fused pyrimidines of general formula (10), wherein R^1 , X, Q, V, R^8 , R^9 , D, and E are as defined in formula (I), can be prepared according to the method of Scheme 4. A carbonyl component of general formula (9) can be treated with an aldehyde of general formula (2) and an amino heterocycle of general formula (3) in a solvent such as ethanol, acetonitrile or dimethylformamide with heating to provide fused pyrimidines of general formula (10).

20

Scheme 5



Fused pyrimidines of general formula (13), wherein R¹, X, R⁸, R⁹, and D are as defined in formula (I), can be prepared according to the method of Scheme 5. A dicarbonyl component of general formula (11), wherein R' is selected from Cl and OAc and R is selected from lower alkyl, cyanoalkyl, and carboxy protecting group, can be treated with an aldehyde of general formula (2) and an amino heterocycle of general formula (3) in a solvent such as ethanol, acetonitrile or dimethylformamide with heating to provide fused pyrimidines of general formula (12). In the case where R' is OAc, cleavage of the acetyl group may be required to induce cyclization to provide fused pyrimidines of general formula (13). In the case where R' is Cl, cyclization can proceed directly without the isolation of (12) to provide fused pyrimidines of general formula (13).


Many of the starting aryl and heteroaryl aldehydes necessary to carry out the methods described in the preceding and following Schemes may be purchased from commercial sources or may be synthesized by known procedures found in the chemical literature. Appropriate literature references for the preparation of aryl and heteroaryl aldehydes may be found in the following section or in the Examples. For starting materials not previously described in the literature the following Schemes are intended to illustrate their preparation through a general method.

The preparation of aldehydes used to synthesize many preferred compounds of the invention may be found in the following literature references: Pearson, Org. Synth. Coll. Vol

V (1973), 117; Nwaukwa, Tetrahedron Lett. (1982), 23, 3131; Badder, J. Indian Chem. Soc. (1976), 53, 1053; Khanna, J. Med. Chem. (1997), 40, 1634; Rinkes, Recl. Trav. Chim. Pays-Bas (1945), 64, 205; van der Lee, Recl. Trav. Chim. Pays-Bas (1926), 45, 687; Widman, Chem. Ber. (1882), 15, 167; Hodgson, J. Chem. Soc. (1927), 2425; Clark, J. Fluorine Chem. (1990), 50, 411; Hodgson, J. Chem. Soc. (1929), 1635; Duff, J. Chem. Soc. (1951), 1512; Crawford, J. Chem. Soc. (1956), 2155; Tanouchi, J. Med. Chem. (1981), 24, 1149; Bergmann, J. Am. Chem. Soc. (1959), 81, 5641; Other: Eistert, Chem. Ber. (1964), 97, 1470; Sekikawa, Bull. Chem. Soc. Jpn. (1959), 32, 551.

10


Scheme 6



Meta, para-disubstituted aldehydes of general formula (21), wherein R^{10} is selected from alkyl, haloalkyl, halo, haloalkoxy, alkoxy, alkylthio, $-NR^{82}R^{83}$, and $-C(O)NR^{82}R^{83}$ wherein R^{82} and R^{83} are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl and R^{12} is selected from nitro, halo, and alkylcarbonyl, can be prepared according to the method described in Scheme 6. A para substituted aldehyde of general formula (20) or the corresponding acetal protected aldehyde of general formula (22), wherein R is selected from alkyl or together with the oxygen atoms to which they are attached form a 5 or 6 membered ring wherein 1,3-dioxolanes are preferred, may be subjected to conditions of an electrophilic aromatic substitution reaction to provide aldehydes of general formula (21) or

20


protected aldehydes of general formula (23). Preferred protecting groups for compounds of general formula (22) and (23) include dimethyl or diethyl acetals or the 1,3-dioxolanes. These protecting groups can be introduced at the beginning and removed at the end to provide substituted aldehydes of general formula (21) using methods well known to those skilled in the art of organic chemistry.



Aldehydes of general formula (27), wherein R^{10} is selected from alkyl, haloalkyl, halo, haloalkoxy, alkoxy, alkylthio, $-NR^{82}R^{83}$, and $-C(O)NR^{82}R^{83}$ wherein R^{82} and R^{83} are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl and R^{12} is selected from nitro, halo, and alkylcarbonyl, can be prepared by the method described in Scheme 7. A meta substituted phenol (25) is converted to the para substituted salicylaldehyde (26) by reaction with a base such as sodium hydroxide and a reagent such as trichloromethane or tribromomethane, known as the Reimer-Tiemann reaction. An alternate set of reaction conditions involves reaction with magnesium methoxide and paraformaldehyde (Aldred, J. Chem. Soc. Perkin Trans. 1 (1994), 1823). The aldehyde (26) may be subjected to conditions of an electrophilic aromatic substitution reaction to provide meta, para disubstituted salicylaldehydes of general formula (27).


20

Scheme 8



An alternative method of preparing meta, para disubstituted salicylaldehydes of general formula (27), wherein R¹⁰ is selected from alkyl, haloalkyl, halo, haloalkoxy, alkoxy, alkylthio, -NR⁸²R⁸³, and -C(O)NR⁸²R⁸³, wherein R⁸² and R⁸³ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl and R¹² is selected from nitro, halo, and alkylcarbonyl, can be used as described in Scheme 8. A meta, para disubstituted phenol of general formula (28) can be reacted with a base such as sodium hydroxide and a reagent such as trichloromethane or tribromomethane, known as the Reimer-Tiemann reaction, to provide disubstituted salicylaldehydes of general formula (27). An alternate set of reaction conditions involves reaction with magnesium methoxide and paraformaldehyde (Aldred, J. Chem. Soc. Perkin Trans. 1 (1994), 1823).

Scheme 9




15

An alternative method of preparing benzaldehydes of general formula (21), wherein R¹² is selected from alkyl, haloalkyl, chlorine, fluorine, haloalkoxy, alkoxy, alkylthio, nitro, alkylcarbonyl, arylcarbonyl, -NR⁸²R⁸³, and -C(O)NR⁸²R⁸³ wherein R⁸² and R⁸³ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, and R¹⁰ is selected from alkyl, hydroxyalkyl, alkylthio, alkylcarbonyl, and formyl, is described in Scheme 9. Protected benzaldehydes of general formula (29), wherein R is selected from alkyl or together with the oxygen atoms to which they are attached form a 5 or 6 membered ring

20


wherein 1,3-dioxolanes are preferred, can be converted to the 3,4-disubstituted benzaldehyde of general formula (23) via conversion of the bromide to an intermediate lithio or magnesio derivative, followed by reaction with an appropriate electrophile such as an aldehyde, dialkyldisulfide, a Weinreb amide, dimethylformamide, an alkyl halide or other electrophile
 5 followed by deprotection of the acetal to provide benzaldehydes of general formula (21).

Scheme 10




An alternative method of preparing benzaldehydes of general formula (21), wherein
 10 R¹⁰ is selected from alkyl, haloalkyl, chlorine, fluorine, haloalkoxy, alkoxy, alkylthio, -NR⁸²R⁸³, and -C(O)NR⁸²R⁸³ wherein R⁸² and R⁸³ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, R¹² is selected from alkyl, hydroxyalkyl, alkylthio, alkylcarbonyl, arylcarbonyl, and formyl, can be used as described in Scheme 10.
 15 Protected benzaldehydes of general formula (31), wherein R is selected from alkyl or together with the oxygen atoms to which they are attached form a 5 or 6 membered ring wherein 1,3-dioxolanes are preferred can be processed as described in Scheme 9 to provide benzaldehydes of general formula (21).

Scheme 11




Benzaldehydes of general formula (33), wherein R^{10} is selected from hydrogen, alkyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, halo, haloalkoxy, nitro, alkoxy, alkylthio, -
5 $NR^{82}R^{83}$, and $-C(O)NR^{82}R^{83}$ wherein R^{82} and R^{83} are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, and R^{13} is selected from hydrogen, alkyl, arylalkyl, and haloalkyl wherein preferred haloalkyl groups are selected from difluoromethyl, 2,2,2-trifluoroethyl and bromodifluoromethyl, can be prepared as described in Scheme 11. 3-Hydroxybenzaldehyde of general formula (32) can be treated with suitable alkylating reagents
10 such as benzylbromide, iodomethane, 2-iodo-1,1,1-trifluoroethane, chlorodifluoromethane, or dibromodifluoromethane in the presence of base such as potassium carbonate, potassium tert-butoxide or sodium tert-butoxide, to provide benzaldehydes of general formula (33). The synthesis of useful 3-hydroxybenzaldehydes of general formula (32) may be found in the following literature references: *J. Chem. Soc.* (1923), 2820; *J. Med Chem.* (1986), 29, 1982;
15 *Monatsh. Chem.* (1963), 94, 1262; *Justus Liebigs Ann. Chem.* (1897), 294, 381; *J. Chem. Soc. Perkin Trans. 1* (1990), 315; *Tetrahedron Lett.* (1990), 5495; *J. Chem. Soc. Perkin Trans. 1* (1981), 2677.

Scheme 12




Benzaldehydes of general formula (35), wherein R^{12} is selected from hydrogen, alkyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, halo, haloalkoxy, nitro, alkoxy, alkylthio, -
 5 $NR^{82}R^{83}$, and $-C(O)NR^{82}R^{83}$ wherein R^{82} and R^{83} are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, and R^{13} is selected from hydrogen, alkyl, arylalkyl, and haloalkyl wherein preferred haloalkyl groups are selected from difluoromethyl, 2,2,2-trifluoroethyl, and bromodifluoromethyl, can be prepared as described in Scheme 12. 4-Hydroxybenzaldehydes of general formula (34) can be treated with suitable alkylating
 10 reagents such as benzylbromide, iodomethane, 2-iodo-1,1,1-trifluoroethane, chlorodifluoromethane, or dibromodifluoromethane, in the presence of base such as potassium carbonate, potassium tert-butoxide or sodium tert-butoxide to provide benzaldehydes of general formula (35). The synthesis of useful 4-hydroxybenzaldehydes of general formula (34) may be found in the following literature references: Angyal, J. Chem.
 15 Soc. (1950), 2141; Ginsburg, J. Am. Chem. Soc. (1951), 73, 702; Claisen, Justus Liebigs Ann. Chem. (1913), 401, 107; Nagao, Tetrahedron Lett. (1980), 21, 4931; Ferguson, J. Am. Chem. Soc. (1950), 72, 4324; Barnes, J. Chem. Soc. (1950), 2824; Villagomez-Ibarra, Tetrahedron (1995), 51, 9285; Komiyama, J. Am. Chem. Soc. (1983), 105, 2018; DE 87255; Hodgson, J. Chem. Soc. (1929), 469; Hodgson, J. Chem. Soc. (1929), 1641.

20



An alternate method for introduction of substituents at the 3-position of benzaldehydes of general formula (21), wherein R¹⁰ is selected from hydrogen, alkyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, halo, haloalkoxy, nitro, alkoxy, alkylthio, and -C(O)NR⁸²R⁸³, wherein R⁸² and R⁸³ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl can be used as described in Scheme 13. This method, also known as the Sandmeyer reaction, involves converting 3-amino benzaldehydes of general formula (36) to an intermediate diazonium salt with sodium nitrite. The diazonium salts can be treated with a bromine or iodine source to provide the bromide or iodide. The Sandmeyer reaction and conditions for effecting the transformation are well known to those skilled in the art of organic chemistry. The types of R¹² substituents that may be introduced in this fashion include cyano, hydroxy, or halo. In order to successfully carry out this transformation it may in certain circumstances be advantageous to perform the Sandmeyer reaction on a protected aldehyde. The resulting iodide or bromide can be treated with unsaturated halides, boronic acids or tin reagents in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) to provide benzaldehydes of general formula (21). The diazonium salts may also be treated directly with unsaturated halides, boronic acids or tin reagents in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) to provide benzaldehydes of general formula (21).


Scheme 14



An alternate method for introduction of substituents at the 4-position of benzaldehydes of general formula (21), wherein R¹² is selected from hydrogen, alkyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, halo, haloalkoxy, nitro, alkoxy, alkylthio, and -C(O)NR⁸²R⁸³, wherein R⁸² and R⁸³ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, can be used as described in Scheme 14. This method, also known as the Sandmeyer reaction, involves converting 4-amino benzaldehydes of general formula (37) to an intermediate diazonium salt with sodium nitrite and then treating the diazonium salts in a similar manner as that described in Scheme 13. The types of R¹⁰ substituents that may be introduced in this fashion include cyano, hydroxy, or halo. The Sandmeyer reaction and conditions for effecting the transformation are well known to those skilled in the art of organic chemistry. In order to successfully carry out this transformation it may in certain circumstances be advantageous to perform the Sandmeyer reaction on a protected aldehyde.

15

Scheme 15




4-Bromo-3-(trifluoromethoxy)benzaldehyde or 4-chloro-3-(trifluoromethoxy)benzaldehyde can be prepared as described in Scheme 15. The commercially available 4-bromo-2-(trifluoromethoxy)aniline can be protected on the amino group with a suitable N-protecting group well known to those skilled in the art of organic chemistry such as acetyl or tert-butoxycarbonyl. The bromine can then be converted to the

20

lithio or magnesio derivative and reacted directly with dimethylformamide to provide the 4-aminoprotected-3-(trifluoromethoxy)benzaldehyde derivative. Removal of the N-protecting group followed by conversion of the amine to a bromide or chloride via the Sandmeyer method of Scheme 14 provides 4-bromo-3-(trifluoromethoxy)benzaldehyde or 4-chloro-3-(trifluoromethoxy)benzaldehyde.

Scheme 16




4-Trifluoromethylbenzaldehydes of general formula (39), wherein Y is selected from cyano, nitro, and halo may be prepared according to the method of Scheme 16. 4-Trifluoromethylbenzoic acid is first nitrated, using suitable conditions well known in the literature such as nitric acid with sulfuric acid, and the carboxylic acid group reduced with borane to provide 3-nitro-4-trifluoromethylbenzyl alcohol. From this benzyl alcohol may be obtained the 3-nitro-4-trifluoromethylbenzaldehyde by oxidation with typical reagents such as manganese dioxide. The nitro benzylic alcohol can be reduced to the aniline using any of a number of different conditions for effecting this transformation among which a preferred method is hydrogenation over a palladium catalyst. The aniline can be converted to either a halo or cyano substituent using the Sandmeyer reaction described in Scheme 13. Benzyl alcohols of general formula (38) can be oxidized using conditions well known to those skilled

in the art such as manganese dioxide or swern conditions to provide benzaldehydes of general formula (39).

For certain aromatic ring substitutions of R_1 for compounds of the present invention it is preferable to effect transformations of the aromatic ring substitutions after the aldehyde has been incorporated into the core structure of the present invention. As such, compounds of the present invention may be further transformed to other distinct compounds of the present invention. These transformations involve Stille, Suzuki and Heck coupling reactions all of which are well known to those skilled in the art of organic chemistry. Shown below are some representative methods of such transformations of compounds of the present invention to other compounds of the present invention.

Scheme 17




Dihydropyridines of general formula (42), wherein R^8 , R^9 , D , E , Q , V , X , m , and n are as defined in formula (I), R^{10} is selected from hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, chlorine, fluorine, haloalkoxy, nitro, alkoxy, and alkylthio, and $-C(O)NR^{82}R^{83}$ wherein R^{82} and R^{83} are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, R^{11} is selected from hydrogen, hydroxy, alkoxy, haloalkoxy, and arylalkoxy, R^{12} is selected from alkyl, vinyl, aryl, heteroaryl, cyano and the like, can be prepared as described in Scheme 17. Compounds of general formula (41), wherein Y is selected from bromine, iodine, and triflate, are protected with a tert-butoxycarbonyl (Boc) group using standard procedures. The aromatic bromide, iodide, or

triflate can be treated with a suitable tin, boronic acid, or unsaturated halide reagent in the presence of a palladium catalyst with heating in a solvent such as dimethylformamide to effect a coupling reaction that provides dihydropyridines of general formula (42). The conditions for this transformation also effect the removal of the Boc protecting group.

5


Scheme 18



Dihydropyridines of general formula (44), wherein R⁸, R⁹, D, E, Q, V, X, m, and n are as defined in formula (I), R¹² is selected from hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, chlorine, fluorine, haloalkoxy, nitro, alkoxy, alkylthio, and C(O)NR⁸²R⁸³ wherein R⁸² and R⁸³ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, R¹¹ is selected from hydrogen, hydroxy, alkoxy, haloalkoxy, and arylalkoxy, R¹⁰ is selected from alkyl, vinyl, aryl, heteroaryl, cyano and the like, can be prepared as described in Scheme 18. Dihydropyridines of general formula (43), wherein Y is selected from bromine, iodine, and triflate, can be protected with a tert-butoxycarbonyl (Boc) group using standard procedures. The aromatic bromide, iodide, or triflate can be reacted with a suitable tin, boronic acid, or unsaturated halide reagent in the presence of a palladium catalyst with heating in a solvent such as dimethylformamide to effect a coupling reaction that provides dihydropyridines of general formula (44). The conditions for this transformation also effect the removal of the Boc protecting group.

20


Scheme 19



Dihydropyridines of general formula (47), wherein R⁸, R⁹, D, E, Q, V, X, m, and n are as defined in formula (I), R¹⁰ is selected from hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, chlorine, fluorine, haloalkoxy, nitro, alkoxy, alkylthio, and -C(O)NR⁸²R⁸³ wherein R⁸² and R⁸³ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, and R¹¹ is selected from hydrogen, hydroxy, alkoxy, haloalkoxy, and arylalkoxy, can be prepared as described in Scheme 19.


Dihydropyridines of general formula (41), wherein Y is selected from bromine, iodine, and triflate can be protected with a tert-butoxycarbonyl (Boc) group using standard procedures. The aromatic bromide, iodide, or triflate can be treated with a suitable halozinc reagent in the presence of a palladium catalyst with heating in a solvent such as dimethylformamide to effect a coupling reaction that provides dihydropyridines of general formula (47). The conditions for this transformation also effect the removal of the Boc protecting group. The types of meta substituents that may be introduced in this fashion include trihalopropenyl and more specifically the trifluoropropenyl group.

Scheme 20



Dihydropyridines of general formula (48), R⁸, R⁹, D, E, Q, V, X, m, and n are as defined in formula (I), R¹⁰ is selected from hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, chlorine, fluorine, haloalkoxy, nitro, alkoxy, alkylthio, -C(O)NR⁸²R⁸³ wherein R⁸² and R⁸³ are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, R¹¹ is selected from hydrogen, hydroxy, alkoxy, haloalkoxy, and arylalkoxy, can be prepared as described in Scheme 20. Dihydropyridines of general formula (43), wherein Y is selected from bromine, iodine, and triflate can be protected with a tert-butoxycarbonyl (Boc) group using standard procedures. The aromatic bromide, iodide, or triflate can be treated with a suitable halozinc reagent in the presence of a palladium catalyst with heating in a solvent such as dimethylformamide to effect a coupling reaction that provides dihydropyridines of general formula (48). The conditions for this transformation also effect the removal of the Boc protecting group. The types of para substituents that may be introduced in this fashion include trihalopropenyl and more specifically the trifluoropropenyl group.

Scheme 21



Fused pyrimidines of general formula (52), wherein R¹, X, Q, V, R⁸, D, E, m and n are as defined in formula (I) and R⁹ is selected from alkenyl, alkynyl, aryl and heterocycle, can be prepared according to the method of Scheme 21. Fused pyrimidines of general formula (50) may be treated with N-bromosuccinimide (NBS) in a solvent such as methylene chloride to provide bromides of general formula (51). Bromides of general formula (51) may be treated with a palladium (0) catalyst such as tetrakis(triphenylphosphine)palladium (0), an organoborane reagent and a base such as cesium fluoride or potassium carbonate under Suzuki conditions which are known to those of skill in the art (Syn. Comm. 11, 1981, 513; JOC 49, 1984, 5237; Tet. Lett. 26, 1985, 5997; Tet. Lett. 28, 1987, 5093; and Tet. Lett. 28, 1987, 5097) to provide fused pyrimidines of general formula (52). Bromides of general formula (51) may also be treated with a palladium (0) catalyst such as tetrakis(triphenylphosphine)palladium (0) and a tin reagent under Stille conditions which are known to those of skill in the art (JACS 101, 1979, 4992) to provide fused pyrimidines of general formula (52). Bromides of general formula (51) may also be treated with a palladium (0) catalyst, an aryl halide (Br or I) or a heterocyclic halide (Br or I) and a base such as triethylamine under biaryl coupling conditions or Heck conditions which are known to those of skill in the art to provide fused pyrimidines of general formula (52).

The compounds and processes of the present invention will be better understood by reference to the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention. Further, all citations herein are incorporated by reference.

5

Example 1

9-(4-bromo-3-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

A solution of 1,3-cyclohexanedione (0.56 g, 5 mmol), 3-bromo-4-fluorobenzaldehyde (1.01 g, 5 mmol), and 3-aminopyrazole (0.41 g, 5 mmol) in ethanol (5 mL) was heated at reflux for 24 hours. After the reaction mixture was allowed to cool to ambient temperature, the volatiles were evaporated at reduced pressure and the resulting residue was chromatographed on silica gel, eluting with 5% ethanol/methylene chloride to provide 0.9 g (49 %) of the title compound.

¹H NMR (DMSO-d₆) δ 1.94 (m, 2H), 2.25 (m, 2H), 2.63 (m, 2H), 5.72 (d, 1H), 6.19 (s, 1H), 7.1 (m, 1H), 7.23 (t, 1H), 7.31 (d, 1H), 7.4 (dd, 1H), 10.55 (s, 1H); MS (ESI-) m/z: 362 (M-H)⁻; Analysis Calculated for C₁₆H₁₃FBrN₃O: C, 53.06; H, 3.62; N, 11.60. Found: C, 52.92; H, 4.02; N, 11.48.

15

Example 2

9-(3-bromo-4-fluorophenyl)-5,9-dihydro-4H-pyrazolo[1,5-a]thiopyrano[3,4-d]pyrimidin-8(7H)-one

A solution of 3,5-thiopyrandione (0.13 g, 1 mmol) prepared as described in (Fehnel, E.A., J. Amer. Chem. Soc., (1955), 77, 4241-4244), 3-bromo-4-fluorobenzaldehyde (0.203 g, 1 mmol), and 3-aminopyrazole (0.082 g, 1 mmol) in ethanol (2 mL) were heated at reflux for 24 hours. After the reaction mixture was allowed to cool to ambient temperature, the volatiles were evaporated at reduced pressure and the resulting residue was chromatographed on silica gel, eluting with 5% ethanol/methylene chloride to provide 0.045 g (12 %) of the title compound.
mp 160-163 °C;

25

¹H NMR (DMSO-d₆) δ 3.15 (d, 1H), 3.5 (d, 1H), 3.6 (d, 1H), 3.9 (d, 1H), 5.8 (d, 1H), 6.26 (s, 1H), 7.13 (m, 1H), 7.29 (t, 1H), 7.38 (d, 1H), 7.42 (dd, 1H), 10.86 (s, 1H); MS (ESI-) m/z: 380 (M-H)⁻; Analysis Calculated for C₁₅H₁₁BrFN₃OS•0.25C₂H₆O: C, 47.52; H, 3.22; N, 10.73. Found: C, 47.57; H, 2.89; N, 10.29.

5

Example 3

9-(1-naphthyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

A solution of 1,3-cyclohexanedione (0.11 g, 1 mmol), 1-naphthaldehyde (0.16 g, 1 mmol), and 3-aminopyrazole (0.11 g, 1.27 mmol) in ethanol (10 mL) were heated at 80 °C in a sealed 20 mL vial for 3 days. After the reaction mixture was allowed to cool to ambient temperature, the solvent was evaporated at reduced pressure and the resulting residue was chromatographed on silica gel, eluting with 5% ethanol/methylene chloride to provide 0.14 g (44%) of the title compound.

¹H NMR (DMSO-d₆) δ 1.95 (m, 2H), 2.21 (m, 2H), 2.72 (m, 2H), 5.62 (s, 1H), 7.00 (d, 1H), 7.15-7.95 (m, 7H), 8.61 (d, 1H), 10.45 (s, 1H); MS (APCI+) m/z: 316 (M+H)⁺; Analysis Calculated for C₂₀H₁₇N₃O: C, 76.17; H, 5.43; N, 13.32. Found: C, 75.99; H, 5.48; N, 13.27.

15

Example 4

9-(2-naphthyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

2-Naphthaldehyde (0.16 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.16 g (51%) of the title compound.

¹H NMR (DMSO-d₆) δ 1.91 (m, 2H), 2.25 (m, 2H), 2.68 (m, 2H), 5.74 (d, 1H), 6.37 (s, 1H), 7.20-7.90 (m, 8H), 10.50 (s, 1H); MS (APCI+) m/z: 316 (M+H)⁺; Analysis Calculated for C₂₀H₁₇N₃O: C, 76.17; H, 5.43; N, 13.32. Found: C, 75.97; H, 5.50; N, 13.35.

25

Example 5

9-(3,4-dibromophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

A solution of 1,3-cyclohexanedione (0.11 g, 1 mmol), 3,4-dibromobenzaldehyde (0.26 g, 1 mmol) and 3-aminopyrazole (0.11 g, 1.27 mmol) in ethanol (10 mL) was heated at 80 °C

in a sealed 20 mL vial for 3 days. After the reaction mixture was allowed to cool to ambient temperature, the resulting solid was isolated by filtration and recrystallization from acetone to provide 0.23 g (56%) of the title compound.

¹H NMR(DMSO-d₆) 1.91 (m, 2H), 2.25 (m, 2H), 2.64 (m, 2H), 5.78(d, 1H), 6.19(s, 1H), 6.95-7.65 (m, 4H), 10.59 (s, 1H); MS(APCI+) m/z: 423(M+H)⁺; Analysis Calculated for C₁₆H₁₃Br₂N₃O: C, 45.42; H, 3.10; N, 9.93; Br, 37.77. Found: C, 45.17; H, 3.22; N, 9.88; Br, 37.59.

Example 6

10 9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

3,4-Dichlorobenzaldehyde (0.18 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.18 g (55%) of the title compound.

¹H NMR(DMSO-d₆) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.64 (m, 2H), 5.78 (d, 1H), 6.20 (s, 1H), 7.00-7.58 (m, 4H), 10.50 (s, 1H); MS(APCI+) m/z: 334(M+H)⁺; Analysis Calculated for C₁₆H₁₃Cl₂N₃O: C, 57.50; H, 3.92; N, 12.57; Cl, 21.22. Found: C, 57.29; H, 4.06; N, 12.53; Cl, 21.45.

Example 7

20 9-(3-bromophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

3-Bromobenzaldehyde (0.19 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.21 g (60%) of the title compound.

¹H NMR(DMSO-d₆) δ 1.93 (m, 2H), 2.25 (m, 2H), 2.65 (m, 2H), 5.78 (d, 1H), 6.20 (s, 1H), 7.05-7.40 (m, 5H), 10.55 (s, 1H); MS(APCI+) m/z: 344(M+H)⁺; Analysis Calculated for C₁₆H₁₄BrN₃O: C, 55.83; H, 4.10; N, 12.21; Br, 23.21. Found: C, 55.95; H, 4.30; N, 12.14; Br, 23.30.

Example 8

9-(3-chlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

3-Chlorobenzaldehyde (0.14 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.17 g (49%) of the title compound.

¹H NMR(DMSO-d₆) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.65 (m, 2H), 5.75 (d, 1H), 6.20 (s, 1H), 7.02-7.38 (m, 5H), 10.55 (s, 1H); MS(APCI+) m/z: 300(M+H)⁺; Analysis Calculated for C₁₆H₁₄ClN₃O: C, 64.11; H, 4.71; N, 14.02; Cl, 11.83. Found: C, 63.81; H, 4.82; N, 14.30; Cl, 11.96.

Example 9

10 9-[4-chloro-3-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4-Chloro-3-trifluoromethylbenzaldehyde (0.21 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.17 g (45%) of the title compound.

15 ¹H NMR(DMSO-d₆) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.65 (m, 2H), 5.78 (d, 1H), 6.30 (s, 1H), 7.30-7.61 (m, 4H), 10.59 (s, 1H); MS(APCI+) m/z: 368 (M+H)⁺; Analysis Calculated for C₁₇H₁₃ClF₃N₃O: C, 55.52; H, 3.56; N, 11.43; Cl, 9.64; F, 15.50. Found: C, 55.50; H, 3.67; N, 11.59; Cl, 9.68; F, 15.15.

Example 10

20 9-[4-fluoro-3-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4-Fluoro-3-trifluoromethylbenzaldehyde (0.19 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.16 g (46%) of the title compound.

25 ¹H NMR(DMSO-d₆) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.65 (m, 2H), 5.79 (d, 1H), 6.29 (s, 1H), 7.35-7.48 (m, 4H), 10.60 (s, 1H); MS(APCI+) m/z: 352(M+H)⁺; Analysis Calculated for C₁₇H₁₃F₄N₃O: C, 58.12; H, 3.73; N, 11.96; F, 21.63. Found: C, 54.49; H, 3.90; N, 11.07; F, 22.79.

Example 11

9-[3-(trifluoromethoxy)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

3-Trifluoromethoxybenzaldehyde (0.19 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.17 g (50%) of the title compound.

¹H NMR(DMSO-d₆) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.65 (m, 2H), 5.78 (d, 1H), 6.25 (s, 1H), 7.05-7.40 (m, 5H), 10.05 (s, 1H); MS(APCI+) m/z: 350(M+H)⁺; Analysis Calculated for C₁₇H₁₄F₃N₃O₂: C, 58.45; H, 4.04; N, 12.03; F, 16.32. Found: C, 58.43; H, 3.93; N, 11.90; F, 15.92.

Example 12

9-(3-cyanophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

10 3-Cyanobenzaldehyde (0.13 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.16 g (55%) of the title compound.

¹H NMR(DMSO-d₆) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.65 (m, 2H), 5.78 (d, 1H), 6.25 (s, 1H), 7.30-7.66 (m, 5H), 10.60 (s, 1H); MS(APCI+) m/z: 291 (M+H)⁺; Analysis Calculated for C₁₇H₁₄N₄O: C, 70.33; H, 4.86; N, 19.30. Found: C, 70.31; H, 4.95; N, 19.36.

15

Example 13

9-(3-methylphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

3-Methylbenzaldehyde (0.12 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.17 g (60%) of the title compound.

20 ¹H NMR (DMSO-d₆) 1.90 (m, 2H), 2.21 (s, 3H), 2.24 (m, 2H), 2.61 (m, 2H), 5.70 (d, 1H), 6.19 (s, 1H), 6.85-7.30 (m, 5H), 10.40 (s, 1H); MS (APCI+) m/z: 280 (M+H)⁺; Analysis Calculated for C₁₇H₁₇N₃O: C, 73.10; H, 6.13; N, 15.04. Found: C, 72.92; H, 6.17; N, 15.35.

Example 14

25 8-(3-bromo-4-fluorophenyl)-5,8-dihydro-4H,7H-furo[3,4-d]pyrazolo[1,5-a]pyrimidin-7-one

A solution of methyl 4-chloroacetate (0.108 g, 1 mmol), 3-bromo-4-fluorobenzaldehyde (0.203 g, 1 mmol) and 3-aminopyrazole (0.082 g, 1 mmol) in ethanol (2 mL) was heated at reflux for 24 hours. After the reaction mixture was allowed to cool to ambient temperature, the volatiles were evaporated at reduced pressure and the resulting

residue was chromatographed on silica gel, eluting with 5% ethanol/methylene chloride to provide 0.045 g (12 %) of the title compound.

¹H NMR (DMSO-d₆) δ 5.02 (q, 2H), 5.85 (d, 1H), 6.3 (s, 1H), 7.25 (m, 1H), 7.31 (t, 1H), 7.39 (d, 1H), 7.52 (dd, 1H), 11.08 (s, 1H); MS (ESI+) m/z: 352 (M+H)⁺; Analysis Calculated for C₁₄H₉BrFN₃O₂: C, 48.02; H, 2.59; N, 12.00. Found: C, 48.40; H, 2.87; N, 11.65.

Example 15

(-) 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 1 (0.6 g) was chromatographed on a Chiracel OD 4.6 x 250 Prep Model column, eluting with 10% ethanol/hexane to provide 0.259 g of the title compound (retention time 12.0 min).

[α]_D²³ -35.85° (DMSO); ¹H NMR (DMSO-d₆) δ 1.93 (m, 2H), 2.25 (m, 2H), 2.62 (m, 2H), 5.72 (d, 1H), 6.19 (s, 1H), 7.1 (m, 1H), 7.22 (t, 1H), 7.31 (d, 1H), 7.4 (dd, 1H), 10.55 (s, 1H); MS (ESI+) m/z: 362 (M+H)⁺; Analysis Calculated for C₁₆H₁₃N₃BrFO: C, 53.06; H, 3.62; N, 11.60. Found: C, 52.83; H, 3.77; N, 11.28.

Example 16

(+) 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 1 (0.6 g) was chromatographed on a Chiracel OD 4.6 x 250 Prep Model column, eluting with 10% ethanol/hexane to provide 0.252 g of the title compound (retention time 14.639 min).

[α]_D²³ +35.88° (DMSO); ¹H NMR (DMSO-d₆) δ 1.92 (m, 2H), 2.25 (m, 2H), 2.55 (m, 2H), 5.72 (d, 1H), 6.19 (s, 1H), 7.1 (m, 1H), 7.23 (t, 1H), 7.32 (d, 1H), 7.4 (dd, 1H), 10.55 (s, 1H); MS (ESI+) m/z: 362 (M+H)⁺; Analysis Calculated for C₁₆H₁₃N₃BrFO: C, 53.06; H, 3.62; N, 11.60. Found: C, 52.81; H, 3.72; N, 11.54.

Example 17

9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydro-4H-pyrazolo[1,5-a]thiopyrano[3,2-d]pyrimidine 8,8-dioxide

A solution of tetrahydrothiopyran-3-one-1,1-dioxide (0.74 g, 5 mmol), 3-bromo-4-fluorobenzaldehyde (1.01 g, 5 mmol), and 3-aminopyrazole (0.41 g, 5 mmol) in ethanol (5 mL) was heated at reflux for 24 hours. After the reaction mixture was allowed to cool to ambient temperature, the solid that precipitated was filtered off, washed with ethanol, and dried to provide the title compound.

$^1\text{H NMR}$ (DMSO- d_6) δ 2.23 (m, 2H), 2.63 (m, 2H), 3.26 (m, 1H), 3.42 (m, 1H), 5.63 (d, 1H), 6.32 (s, 1H), 7.22 (m, 1H), 7.3 (d, 1H), 7.31 (t, 1H), 7.48 (dd, 1H), 10.17 (s, 1H); MS (ESI+) m/z : 400 (M+H) $^+$; Analysis Calculated for $\text{C}_{15}\text{H}_{13}\text{N}_3\text{BrFO}_2\text{S}$: C, 45.11; H, 3.26; N, 10.53. Found: C, 45.13; H, 3.50; N, 10.40.

Examples 18-53 were prepared according to General Procedure A

General Procedure A

1,3-Cyclohexanedione or 4,4-dimethyl-1,3-cyclohexanedione (0.2-0.5 mmol), an aldehyde (0.2-0.5 mmol) and 3-aminopyrazole (0.2-0.5 mmol) in absolute ethanol (2 mL) were combined in a 1:1:1 molar ratio and heated at 80 °C for 3 days. The mixture was allowed to cool to ambient temperature and the solvent was removed by evaporation at reduced pressure. The crude products were purified by either flash column chromatography (5% MeOH in methylene chloride as eluent), recrystallization from ethanol or preparative TLC (5% MeOH in methylene chloride as solvent).

Example 18

9-(3-chloro-4-hydroxyphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

1,3-Cyclohexanedione, 3-chloro-4-hydroxybenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

$^1\text{HNMR}$ (DMSO- d_6) 1.95 (m, 2H), 2.25 (m, 2H), 2.65 (m,2H), 5.70 (s, 1H), 6.07 (s, 1H), 6.80-6.90 (m, 2H), 7.00 (s, 1H), 7.24 (s, 1H); MS(APCI+) m/z : 316 (M+H) $^+$.

Example 19

3-bromo-9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 1 and N-bromosuccinimide were processed as described in Example 48 to provide the title compound.

^1H NMR(DMSO- d_6) 1.94 (m, 2H), 2.25 (m, 2H), 2.70 (m, 2H), 6.19 (s, 1H), 7.12 (m, 1H), 7.25 (m, 1H), 7.44 (s, 1H), 7.46 (m, 1H); MS(APCI+) m/z: 439 (M+H) $^+$.

5

Example 20

9-(3-chloro-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

1,3-Cyclohexanedione, 3-chloro-4-fluorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

10 ^1H NMR (DMSO- d_6) δ 10.54 (s, 1H), 7.24-7.33 (m, 3H), 7.04-7.10 (m, 1H), 6.19 (s, 1H), 5.73 (d, 1H), 2.55-2.71 (m, 2H), 2.18-2.33 (m, 2H), 1.82-2.01 (m, 2H); MS (APCI+) m/z: 318 (M+H) $^+$.

Example 21

15 9-(3,4-difluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

1,3-Cyclohexanedione, 3,4-difluorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

^1H NMR (DMSO- d_6) δ 10.53 (s, 1H), 7.25-7.33 (m, 2H), 7.08-7.17 (m, 1H), 6.19 (s, 1H), 5.72 (d, 1H), 2.55-2.71 (m, 2H), 2.18-2.2.34 (m, 2H), 1.82-2.01 (m, 2H); MS (APCI+) m/z: 20 302 (M+H) $^+$.

Example 22

9-(4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

25 1,3-Cyclohexanedione, 4-fluorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

^1H NMR (DMSO- d_6) δ 10.46 (s, 1H), 7.39 (d, 1H), 7.11-7.16 (m, 2H), 7.01-7.08 (m, 2H), 6.19 (s, 1H), 5.70 (d, 1H), 2.60-2.69 (m, 2H), 2.18-2.34 (m, 2H), 1.82-2.01 (m, 2H); MS (APCI+) m/z: 284 (M+H) $^+$.

Example 239-[4-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

1,3-Cyclohexanedione, 4-trifluoromethylbenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

5 ¹H NMR (DMSO-d₆) δ 10.56 (s, 1H), 7.61 (d, 2H), 7.32 (d, 2H), 6.26 (s, 1H), 5.73 (d, 1H), 2.58-2.69 (m, 2H), 2.19-2.32 (m, 2H), 1.82-2.02 (m, 2H); MS (APCI+) m/z: 334 (M+H)⁺.

Example 249-(4-cyanophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

10 1,3-Cyclohexanedione, 4-cyanobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.60 (s, 1H), 7.71 (d, 2H), 7.28 (d, 2H), 6.25 (s, 1H), 5.74 (d, 1H), 2.55-2.69 (m, 2H), 2.18-2.30 (m, 2H), 1.80-2.00 (m, 2H); MS (APCI+) m/z: 291 (M+H)⁺.

15 Example 25

9-(4-chloro-3-nitrophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

1,3-Cyclohexanedione, 4-chloro-3-nitrobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

20 ¹H NMR (DMSO-d₆) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.62 (m, 2H), 5.79 (d, 1H), 6.25 (s, 1H), 7.20 (m, 2H), 7.6 (m, 1H), 7.8 (m, 1H), 10.6 (s, 1H).

Example 269-(4-chloro-3-fluorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

25 4,4-Dimethyl-1,3-cyclohexanedione, 4-chloro-3-fluorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.45 (s, 1H), 7.45 (t, 1H), 7.31 (d, 1H), 7.11 (dd, 1H), 9.95 (dd, 1H), 6.15 (s, 1H), 5.71 (d, 1H), 2.61-2.70 (m, 2H), 1.80 (t, 2H), 1.02 (s, 3H), 0.94 (s, 3H); MS (APCI+) m/z: 346 (M+H)⁺.

5

Example 27

9-(3-bromo-4-fluorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 3-bromo-4-fluorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

10

¹H NMR (DMSO-d₆) δ 10.48 (s, 1H), 7.40 (dd, 1H), 7.30 (d, 1H), 7.24 (t, 1H), 7.10-7.16 (m, 1H), 6.14 (s, 1H), 5.70 (d, 1H), 2.62-2.71 (m, 2H), 1.80 (t, 2H), 1.02 (s, 3H), 0.94 (s, 3H); MS (APCI+) m/z: 391 (M+H)⁺.

15

Example 28

9-[4-fluoro-3-(trifluoromethyl)phenyl]-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 4-fluoro-3-trifluoromethylbenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

20

¹H NMR (DMSO-d₆) δ 10.53 (s, 1H), 7.35-7.52 (m, 3H), 7.32 (d, 1H), 6.24 (s, 1H), 5.72 (d, 1H), 2.63-2.71 (m, 2H), 1.81 (t, 2H), 1.02 (s, 1H), 0.93 (s, 1H).

Example 29

25

9-(3,4-dichlorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 3,4-dichlorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.49 (s, 1H), 7.50 (d, 1H), 7.31-7.35 (m, 2H), 7.07 (dd, 1H), 6.14 (s, 1H), 5.71 (d, 1H), 2.62-2.75 (m, 2H), 1.80 (t, 2H), 1.02 (s, 3H), 0.94 (s, 3H); MS (APCI+) m/z: 363 (M+H)⁺.

5

Example 30

9-(4-chloro-3-nitrophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 4-chloro-3-nitrobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

10

¹H NMR (DMSO-d₆) δ 10.55 (s, 1H), 7.81 (d, 1H), 7.65 (d, 1H), 7.45 (dd, 1H), 7.33 (d, 1H), 6.24 (s, 1H), 5.73 (d, 1H), 2.61-2.73 (m, 2H), 1.82 (t, 2H), 1.02 (s, 3H), 0.94 (s, 3H); MS (APCI+) m/z: 373 (M+H)⁺.

15

Example 31

9-(3,4-dibromophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 3,4-dibromobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

20

¹H NMR (DMSO-d₆) δ 10.51 (s, 1H), 7.62 (d, 1H), 7.47 (d, 1H), 7.31 (d, 1H), 7.02 (dd, 1H), 6.12 (s, 1H), 5.71 (d, 1H), 2.59-2.74 (m, 2H), 1.80 (t, 2H), 1.02 (s, 3H), 0.94 (s, 3H); MS (APCI+) m/z: 452 (M+H)⁺.

Example 32

9-[3-fluoro-4-(trifluoromethyl)phenyl]-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

25

4,4-Dimethyl-1,3-cyclohexanedione, 3-fluoro-4-trifluoromethylbenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.54 (s, 1H), 7.66 (t, 1H), 7.33 (d, 1H), 7.22 (d, 1H), 7.13 (d, 1H), 6.23 (s, 1H), 5.74 (d, 1H), 2.62-2.72 (m, 2H), 1.81 (t, 2H), 1.03 (s, 3H), 0.94 (s, 3H); MS (APCI+) m/z: 380 (M+H)⁺.

5

Example 33

7,7-dimethyl-9-(3-nitrophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 3-nitrobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

10 ¹H NMR (DMSO-d₆) δ 10.44 (s, 1H), 8.03-8.08 (m, 1H), 7.91-7.94 (m, 1H), 7.57-7.59 (m, 2H), 7.33 (d, 1H), 6.30 (s, 1H), 5.74 (d, 1H), 2.62-2.72 (m, 2H), 1.75-1.84 (m, 2H), 1.03 (s, 3H), 0.93 (s, 3H); MS (APCI+) m/z: 339 (M+H)⁺.

Example 34

9-(3-cyanophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

15 4,4-Dimethyl-1,3-cyclohexanedione, 3-cyanobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.47 (s, 1H), 7.64-7.69 (m, 1H), 7.54-7.57 (m, 1H), 7.44-7.48 (m, 2H), 7.31 (d, 1H), 6.20 (s, 1H), 5.72 (d, 1H), 2.59-2.76 (m, 2H), 1.81 (t, 2H), 1.02 (s, 3H), 0.92 (s, 3H); MS (APCI+) m/z 319 (M+H)⁺.

20

Example 35

7,7-dimethyl-9-(5-nitro-3-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 4-formyl-2-nitrothiophene and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

25 ¹H NMR (DMSO-d₆) δ 10.55 (s, 1H), 7.68 (d, 1H), 7.62 (d, 1H), 6.24 (s, 1H), 5.72 (d, 1H), 2.62-2.70 (m, 2H), 1.79-1.87 (m, 2H), 1.04 (s, 3H), 1.01 (s, 3H); MS (APCI+) m/z: 345 (M+H)⁺.

Example 36

9-(5-bromo-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 5-bromo-2-hydroxybenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.44 (s, 1H), 9.86 (s, 1H), 7.26 (d, 1H), 7.13 (dd, 1H), 6.93 (d, 1H), 6.66 (d, 1H), 6.30 (s, 1H), 5.66 (d, 1H), 2.60-2.69 (m, 2H), 1.78-1.85 (m, 2H), 1.02 (s, 3H), 0.95 (s, 3H); MS (APCI) m/z: 389 (M+H)⁺.

Example 37

9-(5-chloro-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 5-chloro-2-hydroxybenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.45 (s, 1H), 9.84 (s, 1H), 7.26 (d, 1H), 7.02 (dd, 1H), 6.79 (d, 1H), 6.71 (d, 1H), 6.31 (s, 1H), 5.66 (d, 1H), 2.60-2.70 (m, 2H), 1.76-1.84 (m, 2H), 1.02 (s, 3H), 0.95 (s, 3H); MS (APCI+) m/z: 344 (M+H)⁺.

Example 38

9-(2-hydroxy-5-nitrophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 2-hydroxy-5-nitrobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 11.13 (s, 1H), 10.46 (s, 1H), 7.95 (dd, 1H), 7.87 (d, 1H), 7.25 (d, 1H), 6.86 (d, 1H), 6.38 (s, 1H), 5.66 (d, 1H), 2.64-2.68 (m, 2H), 1.77-1.84 (m, 2H), 1.02 (s, 3H), 0.91 (s, 3H); MS (APCI+) m/z: 355 (M+H)⁺.

Example 399-(3,5-dibromo-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 3,5-dibromo-2-hydroxybenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.79 (s, 1H), 7.59 (d, 1H), 7.42 (d, 1H), 6.65 (d, 1H), 6.42 (s, 1H), 5.81 (d, 1H), 2.60-2.76 (m, 2H), 1.82 (t, 2H), 1.06 (s, 3H), 1.02 (s, 3H); MS (APCI+) m/z: 468 (M+H)⁺.

10

Example 409-(3-bromo-5-chloro-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 3-bromo-5-chloro-2-hydroxybenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 1.02 (s, 3H), 1.06 (s, 3H), 1.84 (t, 2H), 2.62-2.75 (m, 2H), 5.79 (d, 1H), 6.43 (s, 1H), 6.54 (d, 1H), 7.40 (d, 1H), 7.48 (d, 1H), 10.78 (s, 1H); MS (APCI+) m/z: 423 (M+H)⁺.

20

Example 419-(3,5-dichloro-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

4,4-Dimethyl-1,3-cyclohexanedione, 3,5-dichloro-2-hydroxybenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 7.34-7.38 (m, 1H), 6.58 (d, 1H), 6.43 (s, 1H), 5.77 (d, 1H), 2.62-2.81 (m, 2H), 1.83 (t, 2H), 1.05 (s, 3H), 1.00 (s, 3H); MS (APCI+) m/z: 379 (M+H)⁺.

25

Example 427,7-dimethyl-9-(3,4,5-trifluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

5 4,4-Dimethyl-1,3-cyclohexanedione, 3,4,5-trifluorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.

¹H NMR (DMSO-d₆) δ 10.51 (s, 1H), 7.33 (d, 1H), 7.00-7.07 (m, 2H), 6.15 (s, 1H), 5.71 (d, 1H), 2.58-2.77 (m, 2H), 1.82 (t, 2H), 1.02 (s, 3H), 0.96 (s, 3H); MS (APCI+) m/z: 347 (M+H)⁺.

10

Example 439-(3,4-dichlorophenyl)-3-(3-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

15 The product from Example 48 (0.041 g, 0.1 mmol) in dimethoxyethane/methanol (1.5 mL) was treated with 3-fluorophenylboronic acid (0.13 mmol), cesium fluoride (0.2 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.008 g, 0.006 mmol). The mixture was heated at 100 °C for 48 hours and then allowed to cool to ambient temperature. The reaction mixture was filtered through Celite and the filtrate concentrated under reduced pressure. The residue was purified by HPLC chromatography.

20 ¹H NMR (DMSO-d₆) δ 1.95 (m, 2H), 2.28 (m, 2H), 2.75 (m, 2H), 6.2 (s, 1H), 7.10 (m, 2H), 7.3 (m, 1H), 7.4 (m, 3H), 7.65 (s, 1H), 10.5 (s, 1H).

Example 443-(3-chlorophenyl)-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

25

The product from Example 48 and 3-chlorophenylboronic acid were processed as described in Example 43 to provide the title compound.

¹H NMR (DMSO-d₆) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.74 (m, 2H), 6.20 (s, 1H), 7.10 (m, 1H), 7.30 (m, 1H), 7.45-7.55 (m, 4H), 7.65 (s, 1H); MS (APCI+) m/z: 444 (M+H)⁺.

Example 453-(4-carboxyphenyl)-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

5 The product from Example 48 and 4-carboxyphenylboronic acid were processed as described in Example 43 to provide the title compound.

$^1\text{H NMR}$ (DMSO- d_6) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.74 (m, 2H), 6.22 (s, 1H), 7.12 (m, 1H), 7.44 (s, 1H), 7.54 (m, 1H), 7.62 (d, J=8, 2H), 7.77 (m, 1H), 7.98 (d, J=8, 2H); MS (APCI+) m/z: 454 (M+H) $^+$.

10

Example 469-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 48 and 2-tributylstannylthiophene were processed as described in Example 51 to provide the title compound as light yellow solid. $^1\text{H NMR}$ (DMSO- d_6) δ 1.95 (m, 2H), 2.27 (m, 2H), 2.75 (m, 2H), 6.22 (s, 1H), 7.11 (d, 1H), 7.14 (dd, 1H), 7.22 (d, 1H), 7.45 (s, 1H), 7.48 (d, 1H), 7.52 (s, 1H), 7.53 (d, 1H), 10.30 (s, 1H); MS (ESI+) m/z 416 (M + H $^+$); MS (ESI-) m/z 414 (M-H) $^-$ Anal. Calcd for C₂₀H₁₅Cl₂N₃O₃S: C, 57.70; H, 3.63; N, 10.09. Found: C, 57.53; H, 3.46; N, 9.76.

20

Example 479-(3,4-dichlorophenyl)-3-[2-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 48 and 2-(trifluoromethyl)phenylboronic acid were processed as described in Example 43 to provide the title compound.

25 $^1\text{H NMR}$ (DMSO- d_6) δ 1.95 (m, 2H), 2.25 (m, 2H), 2.74 (m, 2H), 6.28 (s, 1H), 7.10 (m, 1H), 7.30 (m, 1H), 7.40-7.95 (m, 5H), 10.22 (s, 1H); MS(APCI+) m/z: 478 (M+H) $^+$.

Example 483-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 6 (0.52 g, 1.56 mmol) in dichloromethane was treated with N-bromosuccinimide (0.28 mg, 1.56 mmol) and allowed to stir at ambient temperature overnight. The mixture was filtered and the filter cake washed with CH₂Cl₂ to provide the title compound (0.54 g) as a solid.

5 ¹H NMR (DMSO-d₆) δ 1.94 (m, 2H), 2.24 (m, 2H), 2.77 (m, 2H), 6.20 (s, 1H), 7.06 (d, J=8, 1H), 7.40 (s, 1H), 7.44 (s, 1H), 7.55 (d, J=8, 1H); MS(APCI+) m/z 411 (M+H)⁺.

Example 49

3-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

10 The product from Example 48 was subjected to chiral column chromatography (Whelko column, 2.11 cm x 25 cm, eluting with 80:20 hexane:(CH₃OH:CH₂Cl₂ 2:1)) to provide two enantiomers. The faster moving enantiomer, retention time 25 minutes, was isolated as an off white solid.

15 ¹H NMR (DMSO-d₆) δ 1.94 (m, 2H), 2.26 (m, 2H), 2.72 (m, 2H), 6.18 (s, 1H), 7.07 (d, 1H), 7.42 (s, 1H), 7.48 (s, 1H), 7.52 (d, 1H), 10.57 (s, 1H); MS (ESI+) m/z: 412 (M+H)⁺; MS (ESI-) m/z: 410 (M-H)⁻; Anal. Calcd for C₁₆H₁₂BrCl₂N₃O: C, 46.52; H, 2.93; N, 10.17. Found: C, 46.49; H, 3.11; N, 9.92.

Example 50

3-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

20 The product from Example 48 was subjected to chiral column chromatography (Whelko column, 2.11 cm x 25 cm, eluting with 80:20 hexane:(CH₃OH:CH₂Cl₂ 2:1)) to provide two enantiomers. The slower moving enantiomer, retention time 31.2 minutes, was isolated as an off white solid.

25 ¹H NMR (DMSO-d₆) δ 1.94 (m, 2H), 2.26 (m, 2H), 2.72 (m, 2H), 6.18 (s, 1H), 7.07 (d, 1H), 7.42 (s, 1H), 7.48 (s, 1H), 7.52 (d, 1H), 10.57 (s, 1H); MS (ESI+) m/z: 412 (M+H)⁺; MS (ESI-) m/z: 410 (M-H)⁻; Anal. Calcd for C₁₆H₁₂BrCl₂N₃O: C, 46.52; H, 2.93; N, 10.17. Found: C, 46.78; H, 2.92; N, 10.02.

Example 519-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 49 (0.2 g, 0.5 mmol) in DMF (4 mL) was treated with tetrakis(triphenylphosphine)palladium(0) (0.11 g) and 2-tributylstannylthiophene (0.41 g, 1.1 mmol). The reaction mixture was heated at 110 °C for 20 hours. After cooling to ambient temperature, the mixture was filtered through Celite and the filtrate diluted with ethylacetate. The diluted filtrate was washed with brine solution, dried over MgSO₄ and concentrated under reduced pressure. The residue was chromatographed on silica gel eluting with hexane:ethylacetate (1:1) to yield 0.14 g of the title compound as a light yellow solid.

¹H NMR (DMSO-d₆) δ 1.95 (m, 2H), 2.27 (m, 2H), 2.75 (m, 2H), 6.22 (s, 1H), 7.11 (d, 1H), 7.14 (dd, 1H), 7.22 (d, 1H), 7.45 (s, 1H), 7.48 (d, 1H), 7.52 (s, 1H), 7.53 (d, 1H), 10.30 (s, 1H); MS (ESI+) m/z: 416 (M+H)⁺; MS (ESI-) m/z 414 (M-H)⁻; Anal. Calcd for C₂₀H₁₅Cl₂N₃OS: C, 57.70; H, 3.63; N, 10.09. Found: C, 57.80; H, 3.70; N, 9.86.

Example 529-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 50 was processed as described in Example 51 to provide the title compound as a light yellow solid.

¹H NMR (DMSO-d₆) δ 1.95 (m, 2H), 2.27 (m, 2H), 2.75 (m, 2H), 6.22 (s, 1H), 7.11 (d, 1H), 7.14 (dd, 1H), 7.22 (d, 1H), 7.45 (s, 1H), 7.48 (d, 1H), 7.52 (s, 1H), 7.53 (d, 1H), 10.30 (s, 1H); MS (ESI+) m/z: 416 (M+H)⁺; MS (ESI-) m/z: 414 (M-H)⁻; Anal. Calcd for C₂₀H₁₅Cl₂N₃OS: C, 57.70; H, 3.63; N, 10.09. Found: C, 57.78; H, 3.60; N, 9.85.

Example 539-(3,4-dichlorophenyl)-3-(2-furyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one

The product from Example 6, tetrakis(triphenylphosphine)palladium(0) (0.11 g) and 2-tributylstannylfuran were processed as described in Example 51 to provide the title compound.

^1H NMR (DMSO- d_6) δ 1.95 (m, 2H), 2.28 (m, 2H), 2.78 (m, 2H), 6.22 (s, 1H), 6.57 (dd, 1H), 6.64 (d, 1H), 7.09 (d, 1H), 7.42 (s, 1H), 7.53 (d, 1H), 7.64 (s, 1H), 7.65 (d, 1H), 9.97 (s, 1H); MS (ESI+) m/z 400 (M+H) $^+$; MS (ESI-) m/z 398 (M-H) $^-$; Anal. Calcd for $\text{C}_{20}\text{H}_{15}\text{Cl}_2\text{N}_3\text{O}_2$: C, 60.02; H, 3.78; N, 10.50. Found: C, 60.06; H, 3.76; N, 10.33.

5

Determination of Potassium Channel Opening Activity

Membrane Hyperpolarization Assays

Compounds were evaluated for potassium channel opening activity using primary cultured guinea-pig urinary bladder (GPB) cells.

10 For the preparation of urinary bladder smooth muscle cells, urinary bladders were removed from male guinea-pigs (Hartley, Charles River, Wilmington, MA) weighing 300-400 g and placed in ice-cold Ca^{2+} -free Krebs solution (Composition, mM: KCl, 2.7; KH_2PO_4 , 1.5; NaCl, 75; Na_2HPO_4 , 9.6; $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 8; MgSO_4 , 2; glucose, 5; HEPES, 10; pH 7.4). Cells were isolated by enzymatic dissociation as previously described with minor
15 modifications in (Klockner, U. and Isenberg, G., *Pflugers Arch.* 1985, 405, 329-339), hereby incorporated by reference. The bladder was cut into small sections and incubated in 5 mL of the Krebs' solution containing 1 mg/mL collagenase (Sigma, St. Louis, MO) and 0.2 mg/mL pronase (Calbiochem, La Jolla, CA) with continuous stirring in a cell incubator for 30
20 minutes. The mixture was then centrifuged at 1300 x g for 5 minutes, and the pellet resuspended in Dulbecco's PBS (GIBCO, Gaithersburg, MD) and recentrifuged to remove residual enzyme. The cell pellet was resuspended in 5 mL growth media (composition: Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 units/mL streptomycin and 0.25 mg/mL amphotericin B) and further
25 dissociated by pipetting the suspension through a flame-polished Pasteur pipette and passing it through a polypropylene mesh membrane (Spectrum, Houston, TX). The cell density was adjusted to 100,000 cells/mL by resuspension in growth media. Cells were plated in clear-bottomed black 96-well plates (Packard) for membrane potential studies at a density of 20,000 cells/well and maintained in a cell incubator with 90% air:10% CO_2 until confluent. Cells

were confirmed to be of smooth muscle type by cytoskeletal staining using a monoclonal mouse anti human- α -smooth muscle actin (Biomed, Foster City, CA).

Functional activity at potassium channels was measured by evaluating changes in membrane potential using the bis-oxonol dye DiBAC(4)₃ (Molecular Probes) in a 96-well cell-based kinetic assay system, Fluorescent Imaging Plate Reader (FLIPR) (K.S. Schroeder et al., J. Biomed. Screen., v. 1 pp. 75-81 (1996)), hereby incorporated by reference.

DiBAC(4)₃ is an anionic potentiometric probe which partitions between cells and extracellular solution in a membrane potential-dependent manner. With increasing membrane potential (for example, K⁺ depolarization), the probe further partitions into the cell; this is measured as an increase in fluorescence due to dye interaction with intracellular lipids and proteins.

Conversely, decreasing membrane potential (hyperpolarization by potassium channel openers) evokes a decrease in fluorescence.

Confluent guinea-pig urinary bladder cells cultured in black clear-bottomed 96-well plates were rinsed twice with 200 mL assay buffer (composition, mM: HEPES, 20; NaCl, 120; KCl, 2; CaCl₂, 2; MgCl₂, 1; glucose, 5; pH 7.4 at 25 °C) containing 5 μ M DiBAC(4)₃ and incubated with 180 mL of the buffer in a cell incubator for 30 minutes at 37 °C to ensure dye distribution across the membrane. After recording the baseline fluorescence for 5 minutes, the reference or test compounds, prepared at 10 times the concentration in the assay buffer, were added directly to the wells. Changes in fluorescence were monitored for an additional 25 minutes. Hyperpolarization responses were corrected for any background noise and were normalized to the response observed with 10 μ M of the reference compound P1075, N''-cyano-N-(tert-pentyl)-N'-(3-pyridinyl)guanidine, which was assigned as 100%. P1075 is a potent opener of smooth muscle K_{ATP} channels (Quast et al., Mol. Pharmacol., v. 43 pp. 474-481 (1993)) and was prepared using the procedures described in (Manley, J. Med. Chem. (1992) 35, 2327-2340), hereby incorporated by reference.

Routinely, five concentrations of P1075 or test compounds (log or half-log dilutions) were evaluated and the maximal steady-state hyperpolarization values (expressed as % relative to P1075) plotted as a function of concentration. The EC₅₀ (concentration that elicits 50% of the maximal response for the test sample) values were calculated by non-linear

regression analysis using a four parameter sigmoidal equation. The maximal response of each compound (expressed as % relative to P1075) is reported. Stock solutions of compounds were prepared in 100% DMSO and further dilutions were carried out in the assay buffer and added to a 96-well plate. The maximal steady-state hyperpolarization values (expressed as % relative to P1075) and the EC₅₀ values for representative compounds of the present invention are shown in Table 1.

Table 1
Membrane Hyperpolarization (MHP) in Guinea-Pig Bladder (GPB) Cells

Example #	Maximal Response (% P1075)	EC ₅₀ (μ M)
1	87	0.031
2	100	0.040
3	34	24
4	96	0.429
5	98	0.122
6	95	0.130
7	98	0.550
8	92	1.12
9	94	0.187
10	100	0.290
11	90	1.71
12	85	2.86
13	50	10
14	89	0.258
15	103	0.051
16	105	0.020
17	89	0.910

18	74	5.5
19	81	0.39
20	83	0.26
21	75	2.3
22	59	7.8
25	66	0.31
26	75	0.34
27	99	0.036
28	96	0.28
29	100	0.045
30	113	0.37
31	96	0.001
32	92	0.16
33	58	7.3
34	38	16
36	103	0.34
38	69	4.6
39	110	1.5
40	107	1.4
41	103	1.4
42	105	0.23
43	95	3.2
44	87	2.5
45	106	0.27
46	118	0.038
48	113	0.033

In vitro Functional models

Compounds of the present invention were evaluated for functional potassium channel opening activity using tissue strips obtained from Landrace pig bladders.

Landrace pig bladders were obtained from female Landrace pigs of 9-30 kg. Landrace pigs were euthanized with an intraperitoneal injection of pentobarbital solution, Somlethal[®],
5 J.A. Webster Inc., Sterling MA. The entire bladder was removed and immediately placed into Krebs Ringer bicarbonate solution (composition, mM: NaCl, 120; NaHCO₃, 20; dextrose, 11; KCl, 4.7; CaCl₂, 2.5; MgSO₄, 1.5; KH₂PO₄, 1.2; K₂EDTA, 0.01, equilibrated with 5% CO₂/95% O₂ pH 7.4 at 37 °C). Propranolol (0.004 mM) was included in all of the assays to block β-adrenoceptors. The trigonal and dome portions were discarded. Strips 3-5 mm wide
10 and 20 mm long were prepared from the remaining tissue cut in a circular fashion. The mucosal layer was removed. One end was fixed to a stationary glass rod and the other to a Grass FT03 transducer at a basal preload of 1.0 gram. Two parallel platinum electrodes were included in the stationary glass rod to provide field stimulation of 0.05 Hz, 0.5 milli-seconds at 20 volts. This low frequency stimulation produced a stable twitch response of 100-500
15 centigrams. Tissues were allowed to equilibrate for at least 60 minutes and primed with 80 mM KCl. A control concentration response curve (cumulative) was generated for each tissue using the potassium channel opener P1075 as the control agonist. P1075 completely eliminated the stimulated twitch in a dose dependent fashion over a concentration range of 10⁻⁹ to 10⁻⁵ M dissolved in DMSO using 1/2 log increments. After a 60 minute rinsing period, a
20 concentration response curve (cumulative) was generated for the test agonist in the same fashion as that used for the control agonist P1075. The maximal efficacy of each compounds (expressed as % relative to P1075) is reported. The amount of agent necessary to cause 50% of the agent's maximal response (ED₅₀) was calculated using "ALLFIT" (DeLean et al., Am. J. Physiol., 235, E97 (1980)), hereby incorporated by reference, and agonist potencies were
25 expressed as pD₂ (the negative logarithm). Agonist potencies were also expressed as an index relative to P1075. The index was calculated by dividing the ED₅₀ for P1075 by the ED₅₀ for the test agonist in a given tissue. Each tissue was used for only one test agonist, and the indices obtained from each tissue were averaged to provide an average index of potency. These data are shown in Table 2.

Table 2
Functional Potassium Channel Opening Activity in Isolated Bladder Strips

Example#	Landrace Pig Bladder		
	Efficacy (%P1075)	pD ₂	Index
1	96	6.47	0.26
15	100	6.67	0.21
16	95	6.34	0.28

As shown by the data in Tables 1 and 2, the compounds of this invention reduce
5 stimulated contractions of the bladder and therefore may have utility in the treatment of
diseases prevented by or ameliorated with potassium channel openers.

Compounds of the present invention may exist as stereoisomers wherein, asymmetric
or chiral centers are present. These stereoisomers are "R" or "S" depending on the
configuration of substituents around the chiral carbon atom. The terms "R" and "S" used
10 herein are configurations as defined in IUPAC 1974 Recommendations for Section E,
Fundamental Stereochemistry, Pure Appl. Chem., 1976, 45: 13-30. In particular, the
stereochemistry at the point of attachment of R¹, as shown in formula (I)-(IV), may
independently be either (R) or (S), unless specifically noted otherwise. The present invention
contemplates various stereoisomers and mixtures thereof and are specifically included within
15 the scope of this invention. Stereoisomers include enantiomers and diastereomers, and
mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the
present invention may be prepared synthetically from commercially available starting
materials which contain asymmetric or chiral centers or by preparation of racemic mixtures
followed by resolution well-known to those of ordinary skill in the art. These methods of
20 resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary,
separation of the resulting mixture of diastereomers by recrystallization or chromatography
and liberation of the optically pure product from the auxiliary or (2) direct separation of the
mixture of optical enantiomers on chiral chromatographic columns.

The term "pharmaceutically acceptable carrier," as used herein, means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

The present invention provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration.

Further included within the scope of the present invention are pharmaceutical compositions comprising one or more of the compounds of formula (I)-(IV) prepared and formulated in combination with one or more non-toxic pharmaceutically acceptable compositions. The pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration.

The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), buccally or as an oral or nasal spray. The term "parenterally," as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intraarticular injection and infusion.

Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Suspensions, in addition to the active compounds, may contain suspending agents, as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.

If desired, and for more effective distribution, the compounds of the present invention can be incorporated into slow-release or targeted-delivery systems such as polymer matrices,

liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporation of sterilizing agents in the form of sterile solid compositions, which may be dissolved in sterile water or some other sterile injectable medium immediately before use.

5 The active compounds can also be in micro-encapsulated form, if appropriate, with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound can be admixed with at least one inert diluent
10 such as sucrose, lactose, or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of such composition that they release the
15 active ingredient(s) only, or preferentially, in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

Injectable depot forms are made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug
20 to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a
25 bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or

wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic, parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.

5 In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

Solid dosage forms for oral administration include capsules, tablets, pills, powders,
10 and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating
15 agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate;) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols,
20 sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

25 The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a

certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

5 Compounds of the present invention may also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used. The present
10 compositions in liposome form may contain, in addition to the compounds of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the natural and synthetic phospholipids and phosphatidylcholines (lecithins) used separately or together.

 Methods to form liposomes are known in the art. See, for example, Prescott, Ed.,
15 Methods in Cell Biology, Volume XIV, Academic Press, New York, N. Y., (1976), p 33 et seq.

 The terms "pharmaceutically acceptable salts, esters and amides," as used herein, refer to carboxylate salts, amino acid addition salts, zwitterions, esters and amides of compounds of formula (I)-(IV) which are, within the scope of sound medical judgement, suitable for use in
20 contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.

 The compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. By "pharmaceutically acceptable salt" is meant those salts which are, within the scope of sound medical judgement, suitable for
25 use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66: 1

et seq. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid. Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, 5 camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. 10 Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby 15 obtained. Examples of acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.

Basic addition salts can be prepared in situ during the final isolation and purification 20 of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali 25 metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine,

ethanolamine, diethanolamine, piperidine, piperazine and the like. Preferred salts of the compounds of the invention include phosphate, tris and acetate.

The term "pharmaceutically acceptable ester," as used herein, refers to esters of compounds of the present invention which hydrolyze in vivo and include those that break
5 down readily in the human body to leave the parent compound or a salt thereof. Examples of pharmaceutically acceptable, non-toxic esters of the present invention include C₁-to-C₆ alkyl esters and C₅-to-C₇ cycloalkyl esters, although C₁-to-C₄ alkyl esters are preferred. Esters of the compounds of formula (I)-(IV) may be prepared according to conventional methods. For example, 9-(3,4-dichlorophenyl)-3-(4-carboxyphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-
10 b]quinazolin-8(4H)-one can be treated with an acid, such as HCl, in an alcoholic solvent, such as methanol, to provide the ester 9-(3,4-dichlorophenyl)-3-(4-methoxycarbonylphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one.

The term "pharmaceutically acceptable amide," as used herein, refers to non-toxic amides of the present invention derived from ammonia, primary C₁-to-C₆ alkyl amines and
15 secondary C₁-to-C₆ dialkyl amines. In the case of secondary amines, the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C₁-to-C₃ alkyl primary amides and C₁-to-C₂ dialkyl secondary amides are preferred. Amides of the compounds of formula (I)-(IV) may be prepared according to conventional methods. For example, 9-(3,4-dichlorophenyl)-3-(4-carboxyphenyl)-5,6,7,9-
20 tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one can be treated with a chloroformate, such as isobutylchloroformate, in an organic solvent, such as tetrahydrofuran or methylene chloride at a temperature of about 0 °C to ambient temperature, to provide an intermediate anhydride which can then be treated with an amine, such as dimethylamine, to provide 9-(3,4-
25 dichlorophenyl)-3-(4-dimethylaminocarbonylphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one. It is further intended that amides of the present invention include amino acid and peptide derivatives of the compounds of formula (I), as well.

The term "pharmaceutically acceptable prodrug" or "prodrug," as used herein, represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and

lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use. Prodrugs of the present invention may be rapidly transformed in vivo to the parent compound of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T.

5 Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987), hereby incorporated by reference.

Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile
10 conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants which can be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compound(s) which is
15 effective to achieve the desired therapeutic response for a particular patient, compositions and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve
20 the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

The present invention contemplates pharmaceutically active compounds either chemically synthesized or formed by in vivo biotransformation to compounds of formula (I-
(IV).

25 The compounds of the invention, including but not limited to those specified in the examples, possess potassium channel opening activity in mammals (especially humans). As potassium channel openers, the compounds of the present invention may be useful for the treatment and prevention of diseases such as asthma, epilepsy, male sexual dysfunction, female sexual dysfunction, pain, bladder overactivity, stroke, diseases associated with

decreased skeletal blood flow such as Raynaud's phenomenon and intermittent claudication, eating disorders, functional bowel disorders, neurodegeneration, benign prostatic hyperplasia (BPH), dysmenorrhea, premature labor, alopecia, cardioprotection, coronary artery disease, angina and ischemia.

5 The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat bladder overactivity, sensations of incontinence urgency, urinary incontinence, pollakiuria, bladder instability, nocturia, bladder hyperreflexia, and enuresis may be demonstrated by (Resnick, *The Lancet* (1995) 346, 94-99; Hampel, *Urology* (1997) 50 (Suppl 6A), 4-14; Bosch, *BJU International* (1999) 83 (Suppl 2), 7-9; 10 Andersson, *Urology* (1997) 50 (Suppl 6A), 74-84; Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63; Nurse., *Br. J. Urol.*, (1991) 68, 27-31; Howe, *J. Pharmacol. Exp. Ther.*, (1995) 274, 884-890; Gopalakrishnan, *Drug Development Research*, (1993) 28, 95-127).

 The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat male sexual dysfunction such as male erectile 15 dysfunction, impotence and premature ejaculation may be demonstrated by (Andersson, *Pharmacological Reviews* (1993) 45, 253; Lee, *Int. J. Impot. Res.* (1999) 11(4),179-188; Andersson, *Pharmacological Reviews* (1993) 45, 253; Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63, Vick, *J. Urol.* (2000) 163: 202).

 The ability of the compounds of the present invention, including but not limited to 20 those specified in the examples, to treat female sexual dysfunction such as clitoral erectile insufficiency, vaginismus and vaginal engorgement may be demonstrated by (J.J. Kim, J.W. Yu, J.G. Lee, D.G. Moon, "Effects of topical K-ATP channel opener solution on clitoral blood flow", *J. Urol.* (2000) 163 (4): 240; I. Goldstein and J.R. Berman., "Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency 25 syndromes"., *Int. J. Impotence Res.* (1998) 10:S84-S90).

 The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat benign prostatic hyperplasia (BPH) may be demonstrated by (Pandita, *The J. of Urology* (1999) 162, 943; Andersson; *Prostate* (1997) 30: 202-215).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat premature labor and dysmenorrhoea may be demonstrated by (Sanborn, *Semin. Perinatol.* (1995) 19, 31-40; Morrison, *Am. J. Obstet. Gynecol.* (1993) 169(5), 1277-85; Kostrzewska, *Acta Obstet. Gynecol. Scand.* (1996) 75(10), 886-91; Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat functional bowel disorders such as irritable bowel syndrome may be demonstrated by (Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat asthma and airways hyperreactivity may be demonstrated by (Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63; Buchheit, *Pulmonary Pharmacology & Therapeutics* (1999) 12, 103; Gopalakrishnan, *Drug Development Research*, (1993) 28, 95-127).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat various pain states including but not limited to migraine and dyspareunia may be demonstrated by (Rodrigues, *Br. J. Pharmacol.* (2000) 129(1), 110-4; Vergoni, *Life Sci.* (1992) 50(16), PL135-8; Asano, *Anesth. Analg.* (2000) 90(5), 1146-51; Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63; Gopalakrishnan, *Drug Development Research*, (1993) 28, 95-127; Gehlert, *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.*, (1994) 18, 1093-1102).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat epilepsy may be demonstrated by (Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63; Gopalakrishnan, *Drug Development Research*, (1993) 28, 95-127; Gehlert, *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.*, (1994) 18, 1093-1102).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat neurodegenerative conditions and diseases such as cerebral ischemia, stroke, Alzheimer's disease and Parkinson's disease may be demonstrated by (Lawson, *Pharmacol. Ther.*, (1996) 70, 39-63; Gopalakrishnan, *Drug Development*

Research, (1993) 28, 95-127; Gehlert, Prog. Neuro-Psychopharmacol. & Biol. Psychiat., (1994) 18, 1093-1102; Freedman, The Neuroscientist (1996) 2, 145).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat diseases or conditions associated with decreased skeletal muscle blood flow such as Raynaud's syndrome and intermittent claudication may be demonstrated by (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Dompeling Vasa. Supplementum (1992) 3434; WO9932495).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat eating disorders such as obesity may be demonstrated by (Spanswick, Nature, (1997) 390, 521-25; Freedman, The Neuroscientist (1996) 2, 145).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat alopecia may be demonstrated by (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat myocardial injury during ischemia and reperfusion may be demonstrated by (Garlid, Circ Res (1997) 81(6), 1072-82; Lawson, Pharmacol. Ther., (1996) 70, 39-63; Grover, J. Mol. Cell Cardiol. (2000) 32, 677).

The ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat coronary artery disease may be demonstrated by (Lawson, Pharmacol. Ther., (1996) 70, 39-63, Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).

Aqueous liquid compositions of the present invention are particularly useful for the treatment and prevention of asthma, epilepsy, hypertension, Raynaud's syndrome, male sexual dysfunction, female sexual dysfunction, migraine, pain, eating disorders, urinary incontinence, functional bowel disorders, neurodegeneration and stroke.


When used in the above or other treatments, a therapeutically effective amount of one of the compounds of the present invention can be employed in pure form or, where such

forms exist, in pharmaceutically acceptable salt, ester, amide or prodrug form. Alternatively, the compound can be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable excipients. The phrase "therapeutically effective amount" of the compound of the invention means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgement. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

The total daily dose of the compounds of this invention administered to a human or lower animal may range from about 0.003 to about 10 mg/kg/day. For purposes of oral administration, more preferable doses can be in the range of from about 0.01 to about 5 mg/kg/day. If desired, the effective daily dose can be divided into multiple doses for purposes of administration; consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.

What is claimed is:

1. A compound having formula (I):



- 5 or a pharmaceutically acceptable salt, wherein
- n is an integer of 0-1;
- m is an integer of 1-2;
- provided that when m is 2, n is 0;
- 10 R^1 is selected from the group consisting of aryl and heterocycle;
- Q is selected from the group consisting of $C(O)$, $S(O)$, and $S(O)_2$;
- V is selected from the group consisting of $C(R^6)(R^7)$, O, S, and NR^2 , wherein R^2 is
- 15 selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl wherein R^4 and R^5 are independently selected from the group consisting of hydrogen and lower alkyl;
- 20 R^6 and R^7 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, $-NR^4R^5$, and (NR^4R^5) alkyl;
- 25 R^8 and R^9 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl,

arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl;

5 X is selected from the group consisting of N and CR^3 , wherein R^3 is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, $-NR^4R^5$, and (NR^4R^5) alkyl; and

10 D and E are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, $-NR^4R^5$, and (NR^4R^5) alkyl

15 provided that when Q is S(O) or S(O)₂, then V is C(R⁶)(R⁷).

2. A compound according to claim 1, wherein

R¹ is aryl;

X is CR^3 ; and

20 R³ is hydrogen.


3. A compound according to claim 1, wherein

R¹ is heterocycle;

X is CR^3 ; and

25 R³ is hydrogen.

4. A compound according to claim 1 of formula (II):



(II),

or a pharmaceutically acceptable salt thereof.

5

5. A compound according to claim 4, wherein
 R^1 is heterocycle; and
 Q is C(O).

- 10 6. A compound according to claim 4, wherein
 R^1 is heterocycle; and
 Q is S(O).

- 15 7. A compound according to claim 4, wherein
 R^1 is heterocycle; and
 Q is S(O)₂.

- 20 8. A compound according to claim 4, wherein
 R^1 is heterocycle;
 Q is C(O); and
 V is S.

9. A compound according to claim 4, wherein
R¹ is heterocycle;
Q is C(O);
V is S;
- 5 R⁸ is hydrogen;
R⁹ is hydrogen;
D is hydrogen; and
E is hydrogen.
- 10 10. A compound according to claim 4, wherein
R¹ is heterocycle;
Q is C(O); and
V is CH₂.
- 15 11. A compound according to claim 4, wherein
R¹ is heterocycle;
Q is C(O);
V is CH₂;
D is alkyl; and
- 20 E is alkyl.
12. A compound according to claim 4, wherein
R¹ is heterocycle;
Q is C(O);
- 25 V is CH₂;
D is alkyl;
E is alkyl;
R⁸ is hydrogen; and
R⁹ is hydrogen.

13. A compound according to claim 12 that is 7,7-dimethyl-9-(5-nitro-3-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one.

5 14. A compound according to claim 4, wherein
R¹ is heterocycle;
Q is C(O);
V is CH₂;
R⁸ is hydrogen;
10 R⁹ is hydrogen;
D is hydrogen; and
E is hydrogen.

15 15. A compound according to claim 4, wherein
R¹ is heterocycle;
Q is S(O)₂; and
V is CH₂.

20 16. A compound according to claim 4, wherein
R¹ is heterocycle;
Q is S(O)₂;
V is CH₂;
R⁸ is hydrogen;
R⁹ is hydrogen;
25 D is hydrogen; and
E is hydrogen.

17. A compound according to claim 4, wherein
R¹ is aryl; and
Q is C(O).
- 5 18. A compound according to claim 4, wherein
R¹ is aryl;
Q is C(O); and
V is S.
- 10 19. A compound according to claim 4, wherein
R¹ is aryl;
Q is C(O);
V is S;
R⁸ is hydrogen;
15 R⁹ is hydrogen;
D is hydrogen; and
E is hydrogen.
20. A compound according to claim 18 that is 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-
20 4H-pyrazolo[1,5-a]thiopyrano[3,4-d]pyrimidin-8(7H)-one.
21. A compound according to claim 4, wherein
R¹ is aryl;
Q is C(O); and
25 V is CH₂.

22. A compound according to claim 4, wherein
R¹ is aryl;
Q is C(O);
V is CH₂;
5 D is alkyl; and
E is alkyl.
23. A compound according to claim 4, wherein
10 R¹ is aryl;
Q is C(O);
V is CH₂;
D is alkyl;
E is alkyl;
15 R⁸ is hydrogen; and
R⁹ is hydrogen.
24. A compound according to claim 23 selected from the group consisting of
20 9-(4-chloro-3-fluorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-
b]quinazolin-8(4H)-one;
9-(3-bromo-4-fluorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-
b]quinazolin-8(4H)-one;
9-[4-fluoro-3-(trifluoromethyl)phenyl]-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-
b]quinazolin-8(4H)-one;
25 9-(3,4-dichlorophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-
8(4H)-one;
9-(4-chloro-3-nitrophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-
8(4H)-one;

9-(3,4-dibromophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-[3-fluoro-4-(trifluoromethyl)phenyl]-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

5 7,7-dimethyl-9-(3-nitrophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-cyanophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

10 b]quinazolin-8(4H)-one;

9-(5-chloro-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(2-hydroxy-5-nitrophenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

15 9-(3,5-dibromo-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-bromo-5-chloro-2-hydroxyphenyl)-7,7-dimethyl-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

20 b]quinazolin-8(4H)-one; and

7,7-dimethyl-9-(3,4,5-trifluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one.

25. A compound according to claim 4, wherein

25 R¹ is aryl;

Q is C(O);

V is CH₂; and

R⁹ is aryl.

26. A compound according to claim 4, wherein
R¹ is aryl;
Q is C(O);
V is CH₂;
- 5 R⁹ is aryl;
R⁸ is hydrogen;
D is hydrogen; and
E is hydrogen.
- 10 27. A compound according to claim 26 selected from the group consisting of
9-(3,4-dichlorophenyl)-3-(3-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-
b]quinazolin-8(4H)-one;
3-(3-chlorophenyl)-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-
b]quinazolin-8(4H)-one;
- 15 3-(4-carboxyphenyl)-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-
b]quinazolin-8(4H)-one; and
9-(3,4-dichlorophenyl)-3-[2-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-
b]quinazolin-8(4H)-one.
- 20 28. A compound according to claim 4, wherein
R¹ is aryl;
Q is C(O);
V is CH₂; and
R⁹ is heterocycle.
- 25 29. A compound according to claim 4, wherein
R¹ is aryl;
Q is C(O);
V is CH₂;

R⁹ is heterocycle;

R⁸ is hydrogen;

D is hydrogen; and

E is hydrogen.

5

30. A compound according to claim 29 selected from the group consisting of
9-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-
8(4H)-one;

(+) 9-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-

10 8(4H)-one;

(-) 9-(3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-

8(4H)-one; and

9-(3,4-dichlorophenyl)-3-(2-furyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-

one.

15

31. A compound according to claim 4, wherein

R¹ is aryl;

Q is C(O);

V is CH₂; and

20

R⁹ is halogen.

32. A compound according to claim 4, wherein

R¹ is aryl;

Q is C(O);

25

V is CH₂;

R⁹ is halogen;

R⁸ is hydrogen;

D is hydrogen; and

E is hydrogen.

33. A compound according to claim 32 selected from the group consisting of
3-bromo-9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-
8(4H)-one;
5 3-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-
one;
(+) 3-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-
8(4H)-one; and
(-) 3-bromo-9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-
10 8(4H)-one.
34. A compound according to claim 4, wherein
R¹ is aryl;
Q is C(O);
15 V is CH₂;
R⁸ is hydrogen;
R⁹ is hydrogen;
D is hydrogen; and
E is hydrogen.
- 20 35. A compound according to claim 34 that is selected from the group consisting of
9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
9-(1-naphthyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
9-(2-naphthyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
25 9-(3,4-dibromophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
9-(3,4-dichlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
9-(3-bromophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;
9-(3-chlorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-[4-chloro-3-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-[4-fluoro-3-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

5 9-[3-(trifluoromethoxy)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-cyanophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-methylphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

10 (-) 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

(+) 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3-chloro-4-hydroxyphenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

15 9-(3-chloro-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(3,4-difluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-[4-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one;

9-(4-cyanophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one; and

20 9-(4-chloro-3-nitrophenyl)-5,6,7,9-tetrahydropyrazolo[5,1-b]quinazolin-8(4H)-one.

36. A compound according to claim 4, wherein

R¹ is aryl; and

Q is S(O).

25

37. A compound according to claim 4, wherein

R¹ is aryl; and

Q is S(O)₂.

38. A compound according to claim 4, wherein
 R^1 is aryl;
 Q is $S(O)_2$; and
 V is CH_2 .


5

39. A compound according to claim 4, wherein
 R^1 is aryl;
 Q is $S(O)_2$;
 V is CH_2 ;
 R^8 is hydrogen;
 R^9 is hydrogen;
 D is hydrogen; and
 E is hydrogen.

10

40. A compound according to claim 39 that is 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydro-4H-pyrazolo[1,5-a]thiopyrano[3,2-d]pyrimidine 8,8-dioxide.

41. A compound according to claim 1 of formula (III):



20

(III),

or a pharmaceutically acceptable salt thereof.

42. A compound according to claim 41, wherein
 R^1 is heterocycle; and
 Q is $C(O)$.


25

43. A compound according to claim 41, wherein
R¹ is heterocycle; and
Q is S(O).
- 5 44. A compound according to claim 41, wherein
R¹ is heterocycle; and
Q is S(O)₂.
- 10 45. A compound according to claim 41, wherein
R¹ is aryl; and
Q is C(O).
- 15 46. A compound according to claim 41, wherein
R¹ is aryl;
Q is C(O); and
V is O.
- 20 47. A compound according to claim 41, wherein
R¹ is aryl;
Q is C(O);
V is O;
R⁸ is hydrogen;
R⁹ is hydrogen;
D is hydrogen; and
25 E is hydrogen.
48. A compound according to claim 47 that is 8-(3-bromo-4-fluorophenyl)-5,8-dihydro-4H,7H-furo[3,4-d]pyrazolo[1,5-a]pyrimidin-7-one.

49. A compound according to claim 41, wherein
 R^1 is aryl; and
 Q is S(O).

5 50. A compound according to claim 41, wherein
 R^1 is aryl; and
 Q is S(O)₂.

51. A compound according to claim 1 of formula (IV):



(IV),

or a pharmaceutically acceptable salt thereof.

15 52. A compound according to claim 51, wherein
 R^1 is heterocycle; and
 Q is C(O).

20 53. A compound according to claim 51, wherein
 R^1 is heterocycle; and
 Q is S(O).

25 54. A compound according to claim 51, wherein
 R^1 is heterocycle; and
 Q is S(O)₂.

55. A compound according to claim 51, wherein
R¹ is aryl; and
Q is C(O).
- 5 56. A compound according to claim 51, wherein
R¹ is aryl; and
Q is S(O).
- 10 57. A compound according to claim 51, wherein
R¹ is aryl; and
Q is S(O)₂.
58. A pharmaceutical composition comprising a therapeutically effective amount of a
compound of claim 1 in combination with a pharmaceutically acceptable carrier.
- 15 59. A method of treating a disorder in a host mammal in need of such treatment
comprising administering to the mammal a therapeutically effective amount of a compound of
claim 1.
- 20 60. The method of claim 59 wherein the disorder is selected from the group consisting of
asthma, epilepsy, Raynaud's syndrome, intermittent claudication, migraine, pain, pollakiuria,
bladder instability, nocturia, bladder hyperreflexia, enuresis, alopecia, cardioprotection,
ischemia, eating disorders, functional bowel disorders, and neurodegeneration.
- 25 61. The method of claim 59 wherein the disorder is bladder overactivity.
62. The method of claim 59 wherein the disorder is benign prostatic hyperplasia.
63. The method of claim 59 wherein the disorder is dysmenorrhea.

64. The method of claim 59 wherein the disorder is premature labor.

65. The method of claim 59 wherein the disorder is urinary incontinence.

5

66. The method of claim 59 wherein the disorder is selected from the group consisting of male erectile dysfunction and premature ejaculation.

67. The method of claim 59 wherein the disorder is female sexual dysfunction.

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/US 00/32333

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 C07D495/14 C07D491/14 A61K31/505 A61P9/12
//(C07D487/04, 239:00, 231:00), (C07D495/14, 335:00, 239:00, 231:00),
(C07D491/14, 307:00, 239:00, 231:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 89 06535 A (E. R. SQUIBB & SONS, INC.) 27 July 1989 (1989-07-27) claims 1-9	1-67
A	US 4 918 074 A (Y. TSUDA ET AL.) 17 April 1990 (1990-04-17) cited in the application claims 1-16	1-67
A	EP 0 217 142 A (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.) 8 April 1987 (1987-04-08) cited in the application claims 1-8	1-67
	--- -/--	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *B* document member of the same patent family

Date of the actual completion of the international search

25 January 2001

Date of mailing of the international search report

01/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

Intern | Application No
PCT/US 00/32333

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 011, no. 069, 3 March 1987 (1987-03-03) & JP 61 227584 A (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.), 9 October 1986 (1986-10-09) cited in the application abstract ---	1-67
A	PATENT ABSTRACTS OF JAPAN vol. 012, no. 283, 3 August 1988 (1988-08-03) & JP 63 060985 A (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.), 17 March 1988 (1988-03-17) cited in the application abstract ---	1-67
A	US 5 214 047 A (B. OSTERSEHLT ET AL.) 25 May 1993 (1993-05-25) claims 1-5 -----	1-67

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/32333

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8906535 A	27-07-1989	US 4859676 A	22-08-1989
		US 4870072 A	26-09-1989
		EP 0380592 A	08-08-1990
US 4918074 A	17-04-1990	JP 1729602 C	29-01-1993
		JP 4017198 B	25-03-1992
		JP 60193990 A	02-10-1985
		JP 62270584 A	24-11-1987
		JP 1615442 C	30-08-1991
		JP 2040067 B	10-09-1990
		JP 60246387 A	06-12-1985
		JP 62077387 A	09-04-1987
		AT 56450 T	15-09-1990
		DE 3579673 D	18-10-1990
		EP 0183848 A	11-06-1986
		WO 8504172 A	26-09-1985
		EP 0217142 A	08-04-1987
		ES 2001808 A	16-06-1988
		CA 1271751 A	17-07-1990
		EP 0163240 A	04-12-1985
ES 543361 D	01-07-1987		
ES 8706683 A	16-09-1987		
EP 217142 A	08-04-1987	JP 62270584 A	24-11-1987
		JP 62077387 A	09-04-1987
		ES 2001808 A	16-06-1988
		US 4918074 A	17-04-1990
JP 61227584 A	09-10-1986	NONE	
JP 63060985 A	17-03-1988	EP 0328700 A	23-08-1989
US 5214047 A	25-05-1993	DE 3730718 A	23-03-1989
		AT 74605 T	15-04-1992
		CA 1331608 A	23-08-1994
		DE 3869886 A	14-05-1992
		EP 0307814 A	22-03-1989
		ES 2032317 T	01-02-1993
		JP 1071881 A	16-03-1989